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ABSTRACT
Lester, Deranda Brewer. Ph.D. The University of Memphis. May 2011. Neuronal
Pathways and Receptor Mechanisms Mediating Stimulation-Evoked Striatal Dopamine
Release: Relevance to Deep Brain Stimulation as a Treatment for Parkinson’s Disease.
Major Professor: Charles D. Blaha, Ph.D.
Dopaminergic neurons of the nigrostriatal dopaminergic system, projecting from
the substantia nigra compacta (SNc) to the striatum, serve a critical role in mediating
voluntary motor control. Parkinson’s disease is a neurological disorder characterized by
progressive degeneration of these dopamine neurons, which leads to dopaminergic
deficiencies in the striatum. Reduced striatal dopamine transmission is thought to
increase inhibitory basal ganglia output to the thalamus and subsequently reduce
excitation of cortical motor areas, resulting in impaired motor functioning. Despite
unclear mechanisms, deep brain stimulation (DBS) is an established neurosurgical
approach for effectively treating the parkinsonian motor symptoms. Currently the
subthalamic nucleus (STN) is the most commonly targeted site in these procedures, while
the pedunculopontine tegmental nucleus (PPT) is emerging as a therapeutically beneficial
target when stimulated alone or in combination with the STN. Thus, the connectivity
between these nuclei and the nigrostriatal dopamine system is the focus of the present
paper, with the overarching hypothesis being that the therapeutic benefits of STN/PPT
DBS are mediated, at least in part, by activation of surviving nigrostriatal neurons,
resulting in striatal dopamine release. The present study investigated several neural
pathways and receptor mechanisms involved in mediating STN or PPT stimulationevoked striatal dopamine release using in vivo fixed potential amperometry with carbonfiber recording microelectrodes in the striatum of urethane-anesthetized mice. Overall,
results indicate that STN stimulation evokes striatal dopamine release directly via
iv

excitatory glutamatergic inputs to SNc dopamine cells as well as indirectly by activating
excitatory glutamatergic and cholinergic STN-PPT-SNc pathways, while PPT stimulation
evokes striatal dopamine release directly by activating glutamatergic and cholinergic
pathways to SNc dopamine cells as well as indirectly via activation of glutamatergic and
cholinergic PPT-STN-SNc projections. Understanding the influence of the STN and PPT
on SNc dopamine cell activity and output of the basal ganglia-thalamocortical motor
circuit may lead to novel pharmaceutical therapies as well as a better understanding of the
underlying mechanisms of clinical DBS, which could then improve the therapeutic
efficacy of treatments for Parkinson’s disease.
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PREFACE
This dissertation has been formatted to allow for the separate publication of Chapter 5
and Chapter 6. As such, this dissertation and reference list are written following the
Neuroscience style guidelines.
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Chapter 1. Overview of the Nigrostriatal Dopamine System

The nigrostriatal dopaminergic system projects predominantly from the substantia
nigra compacta (SNc) of the midbrain to the caudate putamen (striatum in the rat) of the
forebrain (Albanese and Minciacchi, 1983). Stimulation of the SNc elicits fast excitatory
responses in striatal neurons (Plenz and Kitai, 1996), while lesions of the SNc reduce
basal levels of extracellular striatal dopamine concentrations (Dentresangle et al., 2001).
In addition, striatal extracellular dopamine concentration is positively correlated with the
degree of dopamine cell loss in the SNc (Altar et al., 1987). Dopamine transmission in
the striatum is most commonly associated with voluntary movements and has been linked
to the selection and initiation of contextually appropriate motor patterns (Hauber, 1998;
Redgrave et al., 1999; Wickens, 1990). Reduced dopamine in the striatum is associated
with motor symptoms of Parkinson’s disease such as difficulty initiating and terminating
movements, gait impairments, and muscular rigidity (Knott et al., 1999; Lev et al., 2003;
Wolters and Francot, 1998), whereas excess dopamine release in the striatum can lead to
repetitive motoric behaviors such as stereotypy, with the degree of intensity of
stereotypical behaviors (e.g. body rearing, head bobbing, and gnawing) being positively
correlated with striatal dopamine release (Sharp et al., 1987).

Physiology of the Basal Ganglia
The basal ganglia are comprised of the striatum, substantia nigra, subthalamic
nucleus (STN), and globus pallidus. Anatomists have made further distinctions based on
structure and function. The substantia nigra has been divided into the SNc and substantia
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nigra reticulata (SNr), while the globus pallidus comprises lateral segments, namely the
globus pallidus externus (GPe) and the globus pallidus internus (GPi). The putative role
of the basal ganglia is to synthesize multiple sources of information from sensual,
emotional, associative brain areas in order to produce a contextually appropriate response
(Bolam et al., 2000). The major input station for the basal ganglia is the striatum, with
the majority of neurons within this area being spiny γ-aminobutyric acid (GABA)
containing projection neurons, 2% of striatal neurons being large cholinergic
interneurons, and the rest being aspiny GABAergic interneurons (Hauber, 1998; Parent
and Hazrati, 1995). The spiny GABAergic neurons are the main targets for most
projections to the striatum (Parent and Hazrati, 1995), with dopamine receptor subtypes
of these cells being both dopamine D1-like (D1 and D5) and D2-like (D2, D3, and D4)
receptors (Wooten, 2001). As illustrated in Fig. 1, the neurons of the striatum project to
other areas within the basal ganglia complex, the GPi and the SNr, via two pathways, a
direct (monosynaptic) connection and an indirect pathway through the external segment
of the globus pallidus (GPe) and the subthalamic nucleus (STN). Striatal neurons in the
direct pathway utilize D1 receptors, whereas those in the indirect pathway utilize D2
receptors (Galvan and Wichmann, 2008; Gerfen et al., 1990). Activation of D1 receptors
stimulates adenylate cyclase activity, thus activating the GABAergic medium spiny
output neurons, whereas activation of D2 receptors inhibits adenylate cyclase, thus
inhibiting GABAergic output neurons (Wooten, 2001). Therefore, the direct (via D1)
and indirect (via D2) pathways have opposing actions, but may reach the same net
outcome of activating motor regions of the cortex. For example, activation of D1
receptors in the direct striatal GABAergic pathway leads to inhibition of GPi/SNr
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inhibitory GABAergic projections to the thalamus, subsequently increasing activity in the
thalamus that, in turn, excites motor areas in the cortex (Gerfen et al., 1990; Mink, 1996;
Wooten, 2001). Alternatively, activation of D2 receptors in the indirect pathway inhibits
striatal inhibitory GABAergic neurons, resulting in disinhibition (excitation) of GPe
inhibitory GABAergic neurons that project to the STN. As a consequence, decreased
activity of the STN excitatory glutamatergic neurons that innervate the GPi/SNr, GPe,
and SNc leads to a reduced inhibitory drive of these nuclei to the thalamus, thereby
indirectly increasing excitation of the motor areas in the cortex (Gerfen et al., 1990;
Mink, 1996; Wooten, 2001). In sum, the net effect of striatal dopamine release from the
nigrostriatal pathway increases thalamocortical activity via direct or indirect reduction of
GPi/SNr activity consequently facilitating voluntary movements (Gerfen et al., 1990).
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Fig. 1. Simplified thalamocortical basal ganglia circuitry depicting the innervation of the
striatum by the nigrostriatal dopaminergic system and its excitatory and inhibitory
influence on the direct (via D1 receptors) and indirect (via D2 receptors) GABAergic
striatal output pathways to the globus pallidus internus/substantia nigra reticulata
(GPi/SNr). The glutamatergic and cholinergic neurons of the pedunculopontine
tegmental nucleus (PPT) connect with the basal ganglia via excitatory projections to the
subthalamic nucleus (STN), substantia nigra compacta (SNc), and GPi/SNr. ACh:
acetylcholine; DA: dopamine; GABA: γ-aminobutyric acid; Glu: glutamate; GPe: globus
pallidus externus; Thal: thalamus.
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STN and PPT Connectivity and Modulation of Striatal Dopamine Release
The STN comprises a relatively small bilateral pair of brain nuclei, located in the
diencephalon close to the dorsal forebrain bundle (Hauber, 1998; Lee et al., 2006). The
majority of STN neurons are projection neurons which are glutamatergic in nature (Albin
et al., 1989; Smith and Parent, 1988; Van der Kooy and Hattori, 1980). The STN
projects to many areas of the basal ganglia, with high amounts of collateralization,
including the globus pallidus, SNr, and the SNc (Deniau et al., 1978; Hauber, 1998).
These connections, specifically the direct excitatory efferent to the SNc, place the STN in
a critical position to regulate dopamine activity in the striatum (Groenewegen and
Berendse, 1990; Hammond et al., 1978; Kita and Kitai, 1987). The STN also projects to
the pedunculopontine tegmental nucleus (PPT), offering an alternate route of mediating
activity of the nigrostriatal dopamine system via the PPT’s connectivity with the basal
ganglia (Groenewegen and Berendse, 1990; Morrizumi and Hattori, 1992). The PPT,
located in the mesopontine region of the hindbrain, contains a heterogeneous population
of cholinergic and glutamatergic neurons. PPT projections to the STN, GPi, SNc, cortex,
and thalamus have been identified, with the densest of these projections going to the SNc
and STN (Charara et al., 1996; Clarke et al., 1997; Lee et al., 2000; Pahapill and Lozano,
2000). This prompts interest in the question of exactly how the STN and PPT may
interact to differentially modulate nigrostriatal dopaminergic neurotransmission given
their extensive interconnectivity and high degree of collateralization with many important
nigrostriatal related structures.
Research supports a contribution of the STN in modulating functional activity of
the nigrostriatal dopamine system. Stimulation of the STN has been shown to alter
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neuronal activity within the SNc of rodents generating both excitatory and inhibitory
postsynaptic potentials (Lee et al., 2004; Nakanishi et al., 1987) and increased firing of
SNc neurons (Benazzou et al., 2000; Hammond et al., 1978; Iribe et al., 1999).
Electrical stimulation of the STN has also been shown to increase dopamine extracellular
levels in the striatum (Lee et al., 2006). Pharmacological activation via microinfusion of
the GABA antagonist bicuculline into the STN produced enhancements in not only STN
neuronal firing, but also in SNc and globus pallidus neuron activity (Chergui et al., 1994;
Robledo and Feger, 1990). Intra-STN infusion of kynurenate, which non-selectively
antagonizes ionotropic glutamate receptors, attenuates spontaneous activity of SNc
neurons (Robledo and Feger, 1990). Most of the aforementioned studies utilized rodents;
however, changes in STN activity have also been shown to significantly affect discharge
patterns of SNc neurons and striatal dopamine release similarly in primates (Charara et
al., 1996; Futami et al., 1995). However, the monosynaptic pathway between the STN
and SNc has shown to be sparse in primates compared to rodents (Sato et al., 2000; Smith
et al., 1990). Thus, changes in SNc discharge patterns following pharmacological
stimulation and inhibition of the STN in primates have been suggested to be mediated
primarily by excitatory SNc afferents from the PPT (Charara et al., 1996; Futami et al.,
1995). The STN and PPT are reciprocally connected with excitatory projections (Futami
et al., 1995; Lee et al., 2000), which have been shown to be both cholinergic and
glutamatergic from the PPT to the STN (Moon-Edley and Graybiel, 1983; Oakman et al.,
1999). In vivo electrochemical studies have previously shown that electrical and
chemical stimulation of the PPT enhances dopamine efflux in the striatum (Forster and
Blaha, 2003; Miller and Blaha, 2004); thus, stimulation of the STN may be increasing
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discharge patterns of SNc dopaminergic neurons and generating striatal dopamine release
indirectly through activation of the PPT.
Evidence illustrating the functional importance of the PPT supports a critical
modulatory role of this brain region in the modulation of nigrostriatal dopaminergic
activity. As noted above, excitatory glutamatergic and cholinergic neuronal cells in the
PPT directly project to dopamine-containing cell bodies in the SNc (Blaha and Winn,
1993; Forster and Blaha, 2003; Moon-Edley and Graybiel, 1983; Oakman et al., 1999).
Pharmacological activation of the PPT with ionotropic glutamate receptor agonists
increases both the firing rate of SNc dopamine neurons (Clarke et al., 1987) and
dopamine metabolism within the striatum as measured by in vivo voltammetry
(Hernandez-Lopez et al., 1992). Electrical stimulation of the PPT has also been shown to
activate STN neurons via cholinergic and glutamatergic projections (Hammond et al.,
1983; Woolf and Butcher, 1986). Therefore, in addition to direct activational inputs to
SNc dopaminergic cells, the PPT may also modulate nigrostriatal dopamine activity in an
indirect manner, through PPT glutamatergic and cholinergic inputs to STN glutamatergic
neurons that, in turn, innervate dopamine-containing cells in the SNc (Bevan and Bolam,
1995; Lee et al., 2000). An understanding of how these brain regions functionally
interact to mediate nigrostriatal dopamine release is essential in enhancing our knowledge
on how these pathways normally function to affect sensory-motor gating in the striatum.
Such an understanding will give insight and greater clarity into neurological disorders
such as Parkinson’s disease which arise as a result of abnormal functioning of the
nigrostriatal dopamine system.
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Behavioral Correlates of Striatal Dopamine Release
Dopamine transmission in the striatum is most commonly associated with normal
voluntary ballistic movements (Wickens, 1990). Increasing striatal dopamine levels with
psychostimulants such as the amphetamines in animals leads to the production of
repetitive and contextually redundant stereotypic behaviors, which includes behaviors
such as repetitive rocking, self-grooming, sniffing, and gnawing. Indeed, early in vivo
microdialysis studies have demonstrated that the presentation of these behaviors is
correlated with abnormally high levels of striatal dopamine release (Sharp et al., 1987).
Furthermore, stereotypy may be induced and subsequently attenuated by microinfusions
of dopamine receptor agonists and antagonists, respectively, into the striatum (Canales
and Graybiel, 2000; Presti et al., 2003). It is thought that dopaminergic receptor agonists
and antagonists infused in the striatum may enhance or reduce GABAergic medium spiny
neurons activity, respectively, ultimately resulting in an enhancement or reduction in
communication to motor cortical areas. Thus, excessive striatal dopamine levels are
thought to alter the output of striatal projection neurons (via the direct or indirect output
pathways) leading to reduced activity of the GPi/SNr, as seen in hyperkinetic disorders
such as Huntington’s disease (Mink, 1996).
In contrast, marked reduction or absence of dopamine in the striatum leads to an
overall increase in activity of the GPi/SNr, which in turn reduces neurotransmission in
motor cortical areas and impairs motor control (Mink, 1996; Wooten, 2001). Animals
treated with 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP), which are commonly used chemicals for inducing
degeneration of nigrostriatal dopamine neurons, demonstrate significantly low levels of
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locomotion as well as muscular rigidity, slowness of movement, and abnormal posture
(Langston et al., 1984; Truong et al., 2006). Thus, these animal models mimic the
neuropathology as well as behavioral symptomology seen in Parkinson’s disease. In
clinical cases of Parkinson’s disease, as well as 6-OHDA-lesioned rats and MPTPlesioned monkeys, administration of indirect dopamine agonists such as levodopa,
dramatically ameliorates motor symptoms (Konitsiotis et al., 2000; Murer et al., 1998;
Olanow et al., 2006). Furthermore, chronic treatment or acute high doses of indirect
dopamine agonists such as levodopa can induce dyskinesias, which can be eliminated by
either lowering the levodopa dose or pharmacologically reducing activity of SNc
dopamine neurons (Obeso et al., 2002). In sum, the ultimate effect of dopamine release
in the striatum, arising from SNc dopamine neurons is to facilitate movement and
regulate motor patterns.

9

Chapter 2. Parkinson’s Disease

Motor Symptoms and Neuropathology of Parkinson’s Disease
Parkinson’s disease is a neurological disorder affecting up to 3 percent of people
aged 65 and over worldwide (Lang and Lozano, 1998; Zhang and Roman, 1993). Mean
age of onset is now thought to be in the early-to-mid 60s, but has in some cases occurred
as early as mid 40s (Inzelberg et al., 2002). Parkinson’s disease is characterized
primarily by motor symptoms that include bradykinesia (slowness in movement), tremor,
rigidity, postural instability, and gait impairments, with nonmotor symptoms such as
sleep disturbances and cognitive impairment appearing also (Jankovic, 2008). The
principal pathology associated with Parkinson’s disease is the degeneration of dopaminecontaining neurons in the substantia nigra compacta (SNc), a critical component of the
nigrostriatal dopamine system (Wolters and Francot, 1998). Degeneration of SNc
dopamine neurons subsequently results in dopamine deficiencies within the caudateputamen (striatum) of the forebrain (Lev et al., 2003). Reduced dopamine levels in the
striatum disrupts the normal functioning of the basal ganglia-thalamocortical motor
circuit, which plays a critical role in regulating motor activity (Knott et al., 1999; Lev et
al., 2003; Wolters and Francot, 1998). Specifically, a reduction in striatal dopaminergic
transmission, as in the parkinsonian condition, is thought to increase inhibitory output
from the basal ganglia to the thalamus leading to a reduction in excitation of primary
motor areas of the cortex, resulting in impaired motor functioning. Fig. 1 depicts changes
in the overall activity of basal ganglia-thalamocortical motor circuit related to
Parkinson’s disease (modified from Galvan and Wichmann, 2008). In Parkinson’s
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disease, the degeneration of SNc dopamine neurons and their projections to the striatum
is a slowly evolving process occurring over decades, a very heinous aspect of this
disease. SNc projections to the areas of the striatum related to motor function degenerate
earlier than projections to associative or limbic portions of the striatum; therefore, the
motor symptoms of Parkinson’s disease develop and are often detectable before the nonmotor symptoms. Clinical motor symptoms are observed with at least 80% decrease in
striatal dopamine content and at least 50% or greater loss of dopaminergic neurons in the
SNc (Fearnley and Lees, 1991; Samii et al., 2004).

Fig. 1. Simplified depiction of Parkinsonism-related changes in overall activity of the
thalamocortical basal ganglia motor circuitry. Blue arrows indicate dopaminergic
projections. Red arrows indicate excitatory glutamatergic projections, and black arrows
indicate inhibitory GABAergic projections. The thickness of the arrows corresponds to
their presumed activity; such that the thicker lines indicate more activation, and the
11

dotted lines indicate less activation. GPe: globus pallidus externus; GPi: globus pallidus
internus; SNc: substantia nigra compacta; SNr: substantia nigra reticulata; STN:
subthalamic nucleus.

Evidence implicating nigrostriatal dysfunction in Parkinson’s disease arises from
a number of sources including postmortem brain analysis and functional imaging
techniques. Post mortem analysis of Parkinsonian brains have demonstrated a marked
degeneration of dopamine-containing cells in the SNc, as well as reduced expression of
dopamine transporters and synaptic vesicle amine transporter gene expression (Fearnley
and Lees, 1991; Knott et al., 1999; Zweig et al., 1989). Interestingly research also
demonstrates significant reductions in neurons within the pedunculopontine tegmental
nucleus (PPT), a hindbrain region which as discussed in Chapter 1 is known to critically
contribute to the functioning of the nigrostriatal dopamine system via its glutamatergic
and cholinergic projections to the SNc (Blaha and Winn, 1993; Chapman et al., 1997;
Jellinger, 1988; Zweig et al., 1989). Additionally, significant loss of neurons within the
PPT has also been found to correlate with the extent of neuronal loss of dopamine cells in
the SNc (Zweig et al., 1989). Structural magnetic resonance imaging (MRI) studies have
noted decreased width of the SNc in Parkinson’s patients (Duguid et al., 1986;
Hutchinson and Raff, 2000), and as expected, volumetric MRI analysis of parkinsonian
brains have shown diminished volumes in subcortical nuclei including the striatum
(Lisanby et al., 1993; Oneill et al., 2002). Functional neuroimaging is mainly used
experimentally but has become useful in clinical trials aimed at measuring the
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progression of Parkinson’s disease (Whone et al., 2003). As measured by positron
emission tomography (PET), Parkinson’s disease is characterized by decreased striatal 6[18F]-fluoro-L-dopa (F-DOPA) uptake (Vingerhoets et al., 1994), which is highly
correlated with reduced dopamine cell counts measured in post mortem brains (Snow et
al., 1993).

Animal Models of Parkinson’s Disease
Animal models of Parkinson’s disease have also yielded strong supporting
evidence for a neuropathology of the nigrostriatal dopamine system in this disorder.
Studies that have selectively lesioned components of the nigrostriatal dopamine system
(e.g. SNc, striatum) through the application of specific neurotoxins, one of the most
common being the catecholamine neurotoxin 6-hydroxydopamine (6-OHDA), have
reported close approximations of the extent of the neurodegeneration seen in Parkinson’s
disease (Cousins and Salamone, 1996; Deumans et al., 2002). At a behavioral level, 6OHDA lesioned animals demonstrate motor abnormalities in skilled and fine movements,
as well as deficits in locomotor activity. Furthermore, such animal models demonstrate
that significant lesions of the nigrostriatal dopamine system that reduce dopamine striatal
tissue content by approximately 80% produce motor difficulties akin with Parkinson’s
disease. Interestingly, excitotoxic lesions of the PPT have also been found to produce
parkinsonian type postural deficits, hypokinesia and locomotor deficits in primates
(Kojima et al., 1997; Pahapill and Lozano, 2000).
Another neurotoxin commonly used to mimic Parkinson’s disease neuropathology
in animals is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). During the early
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1980’s, a number of individuals unwittingly injected a potent pyridine derivative related
to the non-opioid analgesic Demerol which was contaminated with MPTP by virtue of a
sloppy synthesis and sold on the streets as “China White”, a synthetic heroin (Ballard et
al., 1985; Langston et al., 1983). Exposure to MPTP produced selective
neurodegeneration of the nigrostriatal dopamine system resulting in the development of
severe bradykinesia, postural deficits, and motor rigidity similar to that seen in
Parkinson’s disease (Langston et al., 1999; Snow et al., 2000). The serendipitous
discovery of MPTP and its parkinsonian symptoms offered new avenues in researching
Parkinson’s disease, and new MPTP animal models of Parkinson’s disease emerged. The
MPTP primate model of human Parkinson’s disease has also provided additional
evidence that the nigrostriatal dopamine system is particularly important in the etiology
of this disease. MPTP treated primates develop motor abnormalities closely resembling
those seen in humans with Parkinson’s disease, with deficits including bradykinesia,
rigidity, postural abnormalities and postural tremor, and rest tremor in some primate
species (Kanda et al., 2000; Maratos et al., 2001; Schapira, 2002). For this reason, MPTP
administration in primates is considered the most predictive model for antiparkinsonian
efficacy of novel drugs in humans (Gerlach and Riederer, 1996). In sum, animal models
such as these suggest that interfering with neural areas that importantly influence
nigrostriatal dopamine activity may contribute to the severe motor abnormalities
associated with Parkinson’s disease. Also, these animal models have been very useful in
studying the therapeutic strategies for motor symptom treatment and potential
neuroprotection (Betarbet et al., 2002; Schober, 2004; Terzioglu and Galter, 2008).
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Etiology of Parkinson’s Disease
The etiology for the vast majority of Parkinson’s disease cases is largely unknown
and thus classified as idiopathic. Controversy exists as to how much of the disease
results from a strictly genetic cause, a purely environmental factor, or a combination of
the two (Di Monte, 2003; Farrer, 2006). Thus, despite the overwhelming evidence
implicating nigrostriatal dysfunction in Parkinson’s disease, the precise cause for
neuronal loss and deficient dopaminergic activity within the nigrostriatal dopamine
system remains unclear. Several mechanisms have been proposed for the cell death
associated with Parkinson’s disease, including oxidative stress and excitotoxicity.
Oxidative stress is an adverse effect that occurs when the generation of highly reactive
free radicals exceeds the system’s ability to neutralize and eliminate them, resulting in
damage to the cellular membrane lipids, proteins, and DNA (for review see Simonian and
Coyle, 1996). Post mortem brains of Parkinson’s patients have shown increased amounts
of free radical damage indicators, such as lipid peroxidation and oxidized DNA (Alam et
al., 1997; Dexter et al., 1989). 6-OHDA is selectively taken up by dopaminergic neurons
(and other catecholaminergic neurons near site of infusion) and causes oxidative stress
and ultimately cell degeneration (Cohen and Heikkila, 1974). Oxidative stress is also
thought to participate in MPTP-induced toxicity of dopamine neurons (Zang and Misra,
1993). For this reason, antioxidant approaches for neuroprotective therapies seem
warranted and have shown preclinically to protect against MPTP toxicity and 6-OHDA
lesioning in animal models. It is important to note however, clinical trials assessing the
effectiveness of antioxidants as neuroprotective agents for Parkinson’s disease have been
inconclusive, with transient results at best (Alexi et al., 2000).
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It has also been proposed that the neurodegeneration associated with Parkinson’s
disease may result from increased glutamatergic transmission in the SNc, most likely due
to overactivity and burst firing of STN neurons (Johnson et al., 2009). Glutamate
receptors, specifically N-methyl-D-aspartic acid (NMDA) receptors, are known to
mediate excitotoxicity caused by high levels of glutamate. Therefore, activation of these
receptors in the SNc may contribute to the degeneration of dopamine neurons in this
region (Waxman and Lynch, 2005). In support of this argument, NMDA antagonists
have been noted to reduce or delay SNc degeneration and motor deficits caused by MPTP
administration or 6-OHDA lesioning (Johnson et al., 2009). These results support the
hypothesis that NMDA receptor activation contributes to neurodegeneration in
Parkinson’s disease and suggest that blockade of NMDA receptors may be a useful
strategy for slowing disease progression. However, the widespread expression and
diverse functional roles of NMDA receptors raise concern that targeting these receptors
would lead to serious unwanted side effects. Clinical studies have therefore used weak
NMDA receptor antagonists and have generally failed to find any therapeutic benefit
when administered alone (without levodopa) (Johnson et al., 2009). More promising
studies suggest that selectively targeting NMDA receptor subtypes specific to regions
relevant to Parkinson’s disease pathophysiology may represent safer neuroprotective
options (Jin et al., 1997). As such, further clinical studies using more selective drugs
targeting NMDA receptors are needed. In sum, the specific factors that contribute to or
initiate overly active NMDA mechanisms in excitotoxicity are poorly understood, and the
potential contribution of other types of glutamate receptors to the development and
progression of Parkinson’s disease symptoms remains unclear.
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Treatments for the Motor Symptoms of Parkinson’s Disease
The most effective pharmaceuticals for treating the motor symptoms of
Parkinson’s disease are drugs that restore dopaminergic function in the striatum, with the
most commonly prescribed being the dopamine precursor levodopa (Olanow et al., 2004).
Levodopa is usually combined with carbidopa (Lodosyn) or benserazide (Serazide) as
Sinemet or Prolopa, respectively, to prevent peripheral conversion of levodopa to
dopamine by dopa-decarboxylase (Olanow et al., 2004). Dopamine synthesized from
levodopa activates both D1 and D2 receptors in the striatum, which is important
therapeutically as antiparkinsonian drugs with high D2 and low D1 affinity have been
shown to be less effective in reversing motor symptoms compared to levodopa (Wooten,
2001). Conjoint use of levodopa with drugs that inhibit dopamine-degrading enzymes
(e.g. monoamine oxidase inhibitors) within surviving dopamine nerve terminals have
further been shown to enhance the therapeutic effects of levodopa alone, presumably by
slowing the metabolic breakdown of dopamine, while the conjunctive use of
dopaminergic agonists with levodopa has also proved therapeutically beneficial during
later stages of Parkinson’s disease (Hurtig, 1997). In fact, levodopa has been used to
distinguish Parkinson's disease from other conditions that may resemble Parkinson's
disease, a true testament to the reliability of levodopa for treating the motor symptoms of
Parkinson’s disease. Reduced motor symptoms following a single administration of
levodopa can help to confirm the diagnosis of Parkinson’s disease, and a negative
response is thought to be an indication for alternative diagnosis (D’Costa et al., 1995).
While levodopa treatment provides relief of motor symptoms for several years in
most patients, complications occur with long-term use. As dopaminergic neurons
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continue to deteriorate, the levodopa dose is effective for a shorter time, and the patient
experiences “wearing off” sooner. Motor fluctuations can also become unpredictable
with sudden switches between good therapeutic response (i.e. mobility) and no
therapeutic response (i.e. immobility), referred to as the “on-off” phenomenon (Marsden
and Parkes, 1976). Also, increased doses of levodopa leads to abnormal involuntary
movements (e.g. dyskinesia and leg dystonia), which can be lessened by reduction of the
dose, but the dose decrease then generally leads to loss of control of the disease. These
motor complications have an incidence of 10% per year, so that after taking levodopa 5
years roughly 50% of patients experience these detrimental side effects (Rajput et al.,
1984; Rascol et al., 2000). Patients therefore become increasingly disabled even with
treatment, which is a particular problem given that levodopa remains the most effective
treatment for Parkinson’s disease despite these serious drawbacks. Thus, novel
pharmaceuticals as well as interventive neurosurgical treatments, such as deep brain
stimulation, are continuously being explored and refined for better management of the
motor symptoms associated with Parkinson’s disease. Advances in our understanding of
the connectivity and function of the basal ganglia circuitry will continue to open the door
for novel therapeutic strategies.
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Chapter 3. Deep Brain Stimulation as a Treatment for Parkinson’s Disease

Parkinson’s disease is a neurological disorder characterized by a progressive
degeneration of the dopamine neurons in the substantia nigra compacta (SNc) and a
subsequent reduction in striatal dopamine levels (Obeso et al., 2002). Parkinson’s
disease treatments attempt to alleviate symptoms by restoring dopamine transmission in
the striatum (Clarke, 2004). Although oral administration of the dopamine precursor
levodopa, the most commonly prescribed pharmaceutical for ameliorating the motor
symptoms of Parkinson’s disease, is highly effective for several years in most patients, as
the disease progresses with time chronic levodopa treatment is associated with the
development of complications, such as motor fluctuations and dyskinesias, which can be
just as problematic as the disease itself (Marsden and Parkes, 1976; Rascol et al., 2000).
When patients reach this stage, interventive neurosurgery such as deep brain stimulation
(DBS) is an option to consider. Because of the limitations of the current available
pharmaceutical treatments and the efficacy and favorable safety profile of DBS, this
interventive neurosurgical treatment approach is now approved by the US Food and Drug
Administration and is routine in clinical use for treatment of Parkinson’s disease (Krack
et al., 2003). The application and substantial progress of functional neurosurgery rank
amongst the most significant of therapeutic advances in Parkinson’s disease, perhaps
second only to the introduction of levodopa.
DBS involves implanting electrodes with four contacts into the target area of the
brain and connecting it to an implanted pulse generator usually located in the chest area,
much like a pacemaker for the heart. Conventional DBS systems use a relatively high-
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frequency (100-250 Hz) pulse train applied continuously at the site of electrode
implantation (McIntyre et al., 2006). One key aspect permitting reliable therapeutic
benefits of this procedure is that stimulation parameters provided by the implanted pulse
generator can be adjusted postoperatively to improve efficacy, reduce side-effects, and
adapt to the course of the disease. Results from clinical trials have repeatedly shown that
DBS plus medical therapy improves patient quality of life as well as clinical scores on the
Unified Parkinson’s Disease Rating Scale more than the best medical therapy alone
(Deuschl et al., 2006; Weaver et al., 2009; Williams et al., 2010). The most common
target for DBS in Parkinson’s disease is the subthalamic nucleus (STN) as this
ameliorates the cardinal symptoms of the disease (i.e. bradykinesia, rigidity, and tremor)
while at the same time reducing medication needs for the patient (Limousin et al., 1998;
Molineuvo et al., 2000; Moro et al., 1999; Volkmann et al., 2001).

Hypotheses of the Mechanism of Action of DBS
Despite the acceptance of DBS as a well qualified therapeutic tool for treating the motor
symptoms of Parkinson’s disease, the mechanism of action of DBS remains poorly
understood and debated in research. Because the therapeutic effects of DBS are similar
to those of a lesion of targeted nuclei, whether it is the STN (for Parkinson’s disease),
globus pallidus interna (for generalized dystonia), or ventrointermedial nucleus of the
thalamus (for essential tremor), DBS has been thought to silence neurons at the site of
stimulation (Benazzouz et al., 1995; Lozano et al., 2002). However, emerging evidence
is beginning to discredit neuronal silencing hypothesis and, as such, implicates additional
mechanisms of DBS, which involve activation of local neuronal terminals at the site of
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stimulation that inhibit and/or excite efferent outputs. In turn, this has been postulated to
enhance efferent neurotransmission, which may ultimately normalize activity within
structures of the basal ganglia complex (see Benabid, 2003; Lozano and Eltahawy, 2004;
McIntyre et al., 2004; Uc and Follett, 2007). Specifically, recent studies have shown that
DBS results in excitation and altered firing patterns of neurons in the STN (Carlson et al.,
2010; Garcia et al, 2003; Lee et al., 2007), increased activity in dopaminergic neurons of
the SNc (Lee et al., 2003, 2004), as well as enhanced dopamine release in the striatum
(Lee et al., 2006). These findings have lead to the “dopamine release” hypothesis which
proposes that STN DBS improves motor symptoms related to Parkinson’s disease by
activating surviving nigrostriatal dopaminergic neurons and subsequent increases in
striatal dopamine release (Lee et al., 2009). Several studies using in vivo microdialysis
have shown that STN DBS increases dopamine metabolites DOPAC and HVA in the
striatum of normal and 6-hydroxydopamine (6-OHDA) lesioned rats (Meissner et al.,
2001, 2002, 2003; Paul et al., 2000). Furthermore, DBS of the STN decreases or
eliminates the need for levodopa (Molineuvo et al., 2000; Moro et al., 1999) and is most
effective in patients who have responded well to levodopa (Breit et al.,2004), suggesting
that effective DBS requires endogenous dopamine production. Also consistent with the
notion that STN DBS activates surviving nigrostriatal dopamine neurons are clinical
observations that DBS can generate dyskinesias resembling those seen when excess
levodopa is given (Frank et al., 2007).
While supporting evidence from basic research is available, the hypothesis that
DBS of the STN contributes to symptom relief in Parkinson’s disease due to an evoked
increase in striatal dopamine release remains controversial. Two major techniques in
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basic research studies have provided the majority of findings that oppose the dopamine
release hypothesis. First, most basic studies using in vivo microdialysis do not report an
increase in striatal dopamine release during stimulation of the STN in intact or 6-OHDA
lesioned animals (Bruet et al., 2001; Meissner et al., 2001; Paul et al., 2000). Although in
vivo monitoring of slow (min-hrs) changes in dopamine release is easily accomplished
using conventional microdialysis methods, analysis of more rapid changes in dopamine
release that may result from STN DBS requires an equally rapid “real-time” detection
and monitoring system. Second, several positron emission tomography (PET) studies
using [11C]-raclopride binding to measure dopamine release have failed to demonstrate
significant raclopride displacement despite improvements in motor performance
following STN DBS (Abosch et al., 2003; Hilker et al., 2003; Strafella et al., 2003).
However, PET scanning with raclopride has relatively poor temporal resolution and
requires an increase of greater than 90% of baseline measures in order to detect a change
in dopamine receptor populations (Hilker et al., 2003; Volkow et al., 1993). Thus, it
seems likely that inconsistencies in the literature may be due to technical difficulties in
measuring striatal dopamine release. Whether STN DBS improves Parkinson’s disease
motor symptoms via increased release of dopamine in the striatum is the overall focus
connecting the experimental studies in Chapters 5 and 6. For this reason, in order to
avoid the issues of temporal resolution and sensitivity seen in other techniques, these
experimental studies involve real-time monitoring of striatal dopamine release following
electrical stimulation using fixed potential amperometry (FPA), which offers the highest
temporal resolution and sensitivity to monitor changes in dopamine release evoked by
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electrical stimulation of all in vivo neurochemical recording methods to date (Venton et
al., 2002).

Candidate Pathways Mediating DBS-evoked Striatal Dopamine Release
There are several neuronal pathways by which STN DBS could elicit dopamine release in
the striatum. First, stimulation of the glutamatergic input that projects from the STN to
the SNc has been shown to activate nigrostriatal dopaminergic pathways directly
(Meltzer et al., 1997). Second, stimulation of the glutamatergic neurons of the STN
projecting to the pedunculopontine tegmental nucleus (PPT) indirectly activates
nigrostriatal dopamine neurons via reciprocal excitatory innervation back to the STN
which leads to subsequent SNc activation by the aforementioned glutamatergic inputs
(Lee et al., 2000) and by activating excitatory cholinergic and glutamatergic inputs from
the PPT to the SNc (Blaha and Winn, 1993; Forster and Blaha, 2003). As is mentioned in
Chapter 1 and expanded upon in Chapter 5, the interconnectivity between the PPT and
nuclei within the basal ganglia potentially provides the PPT an interesting position in
which to mediate nigrostriatal dopamine activity (Mena-Segovia et al., 2008).
The improvement in motor symptoms in Parkinson’s patients has been correlated
with the location and electrical intensity of chronic stimulation (Garcia et al., 2005), and
therapeutic outcomes of DBS have suggested that the best improvement in symptoms is
obtained when stimulating the white matter corresponding to myelinated axons of
passage in the region of the zona incerta just immediately dorsal to the STN (Saint-Cyr et
al., 2002; Voges et al., 2002). DBS in this region likely results in stimulation of
dopaminergic axons within the medial forebrain bundle (MFB) projecting from the SNc
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to the striatum. Thus, thirdly, DBS of the STN may be activating surviving nigrostriatal
dopamine neurons in Parkinson’s patients via direct stimulation of the MFB. In fact, it
has been postulated that DBS of the MFB may be superior to DBS of the STN in
enhancing dopamine release in the striatum (Lee et al., 2006). These candidate neural
pathways are expanded upon and investigated systematically in the experimental studies
in Chapters 5 and 6. Understanding the underlying mechanisms of DBS and the neural
pathways affected could lead to improvements in stimulation locations and parameters,
which may prove invaluable in improving DBS interventive neurosurgical procedures
and enhancing the clinical efficacy for the treatment of Parkinson’s disease.

24

Chapter 4. Fixed Potential Amperometry Methodology

The experimental studies in Chapters 5 and 6 utilize in vivo fixed potential amperometry
(FPA), an electrochemical method that has been valuable in elucidating the modulation of
forebrain dopamine activity by other neurotransmitter systems (Blaha et al., 1996, 1997;
Floresco et al., 1998; Lester et al., 2008). Like many in vivo amperometric recording
techniques, FPA uses a three-electrode configuration that incorporates an auxiliary
electrode (typically platinum, chrom-alloy or stainless-steel wire), reference electrode
(normally silver/silver chloride) and recording electrode (see Fig. 1) (Blaha and Phillips,
1996). In the experiments of Chapters 5 and 6, the procedure specifically involves the
implantation of a carbon fiber recording electrode and the placement of a silver/silver
chloride reference and stainless-steel auxiliary electrode combination in contact with
brain tissue. An electrometer and analog to digital chart recorder (EA162 Picostat and
ED401 e-corder 401, eDAQ Inc., Colorado Springs, CO, USA; simply referred to as the
electrometer in all other chapters) creates a circuit between the three electrodes, allowing
the application of a fixed continuous potential (+0.8 V) to the recording electrode via the
auxiliary electrode, while maintaining a potential difference between the recording and
reference electrode (Blaha and Phillips, 1992). Continuously applying a potential to the
recording electrode allows dopamine to be continuously oxidized at the electrode surface.
As such, FPA allows a high temporal resolution (10,000 samples/sec or higher dependent
on the analog to digital converter of the recording device) for the analysis of dopamine
neurotransmission in vivo. Pharmacological studies have validated the selectivity of FPA
as a measurement of electrically-stimulated dopamine efflux in vivo (Dugast et al., 1994;
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Forster and Blaha, 2003; Lee et al., 2006). For example, this has been demonstrated by
significant increases in laterodorsal tegmentum stimulation-evoked oxidation current in
the nucleus accumbens and subthalamic nucleus stimulation-evoked oxidation current in
the striatum of rats in response to systemic administration of the dopamine reuptake
inhibitor nomifensine, but not following serotonin or norepinephrine reuptake blockade
with fluoxetine or desipramine (Lee et al., 2006). Consequently, this in vivo technique
has been utilized commonly to evaluate the kinetics of stimulation-evoked dopamine
release and reuptake and drug-induced changes in the magnitude and temporal pattern of
dopamine neurotransmission, as well as the biochemical basis of dopaminergic cell burst
firing in anesthetized rats and mice (Benoit-Marand et al., 2000; Dugast et al., 1994;
Forster and Blaha, 2003; Lee et al., 2006; Lester et al., 2008, 2010; Suaud-Chagny et al.,
1995).
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Fig. 1. Simplified diagram of a three-electrode system used in amperometric
electrochemical recordings. The electrometer applies an electrical potential to the
auxiliary (AUX) electrode that is suitable to oxidize dopamine (DA) at the surface of the
recording electrode (RE), which is held constant relative to the reference electrode (REF).
Oxidized dopamine molecules transfer electrons to the RE which are measured as current
flow via the electrometer (EA162 Picostat) and passed as an analog signal to the analog
to digital chart recorder and (ED401 e-corder 401) where it is converted to a digital signal
for display via Chart software on a computer monitor in near real time. Adapted from
Blaha and Phillips (1996).
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Electrochemical Recording Electrodes Used in FPA
Polyacrylic nitrile, pitch, or pyrolytic-based carbon provides an electrochemically inert
surface covered with oxygen-containing functional groups that facilitate electron transfer
from compounds undergoing oxidation or reduction at the electrode surface (Kawagoe et
al., 1993). Carbon fiber microelectrodes to record stimulation-evoked dopamine release
in vivo were fashioned by threading a single carbon fiber (10 m o.d.) through a
borosilicate glass capillary tube. The tube was then heat-pulled to form a tip through
which the carbon fiber protruded. Carbon paste was packed into the bore of the electrode
and a wire inserted to make contact with the fiber. The wire was secured in place with a
carbon paste (super glue mixed with carbon powder) (see Fig. 2). The protruding carbon
fibers were cut under a stereomicroscope so that the active recording electrode surface
was approximately 250 m long. A new carbon fiber recording electrode was used in
each animal. As a consequence of its small size, the carbon fiber recording electrode
results in minimal tissue damage at the site of insertion and allows for high degree of
local specificity for assessment of regional differences in neurochemical efflux
(Stamford, 1989). Moreover, the small size enables faster sampling of the dopamine
oxidation current as there is less depletion of the neurochemical at the electrode surface
(Forster and Blaha, 2003; Kawagoe et al., 1993).
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Fig. 2. Illustration of the carbon fiber recording electrode fabricated for use in fixed
potential amperometry to monitor the oxidation of dopamine (corresponding to dopamine
efflux) in vivo.

Stereotaxic Surgery and Recording Set-up for FPA
Anesthetized mice are mounted in a stereotaxic frame (David Kopf Instruments, Tujunga,
CA, USA) within a mouse head-holder adaptor (Stoelting, Wood Dale, IL, USA).
Stereotaxic coordinates for each of the target sites, which include the subthalamic nucleus
(STN), medial forbrain bundle (MFB), pedunculopontine tegmental nucleus (PPT),
substantia nigra compacta (SNc), and striatum in Chapters 5 and 6, are determined from
the mouse atlas of Paxinos and Franklin (2001). As shown in Fig. 3, in each mouse a
concentric bipolar stimulating electrode (SNE-100; Rhodes Medical Co., CA, USA), a 31
g stainless-steel guide infusion cannula, and a carbon fiber recording microelectrode is
implanted into the desired brain sites. A silver/silver chloride reference and stainlesssteel auxiliary electrode combination is also placed on contralateral cortical tissue.
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Fig. 3. Schematic diagram of the mouse brain illustrating a typical setup for in vivo fixed
potential amperometric recording of stimulation-evoked striatal dopamine release. In the
experiments in Chapters 5 and 6, a carbon fiber recording electrode is positioned in the
striatum. A stimulating electrode is positioned in the dorsal portion of the medial
forebrain bundle (MFB), subthalamic nucleus (STN), or pedunculopontine tegmental
nucleus (PPT). A silver/silver chloride reference and stainless-steel auxiliary electrode
combination is placed in contact with contralateral cortical tissue, and a drug infusion
cannula is implanted into the PPT, STN, or substantia nigra compacta (SNc).

Amperometric recordings are made within a Faraday cage to increase the signal to
noise ratio (Forster and Blaha, 2003). The stimulation site varies (MFB, STN, or PPT) to
accommodate the aim of each project, but the stimulation protocol consists of twenty 0.5
msec duration pulses at 50 Hz delivered every 30 sec over a 1 hour testing period,
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delivered to the stimulating electrode via an optical isolator and programmable pulse
generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel). With the addition of
microinfusions of drugs, FPA lends itself to the investigation of the role of receptor
subtypes in stimulation-evoked phasic dopamine efflux. Intracerebral infusions of the
local anesthetic lidocaine is an effective means of temporarily blocking all axonal
transmission to or from specific areas and pathways with recovery approximately 10 min
post-infusion (Blaha et al., 1997; Floresco et al., 1998). This drug procedure offers a
unique means to determine the functional neuroconnectivity of DBS-mediated striatal
dopamine release and the relationship between DBS target sites, such as the MFB, STN,
or PPT. By temporarily blocking transmission through one of these sites, it is possible to
determine whether DBS of these structures evokes striatal dopamine transmission via
direct or indirect routes to the SNc. Furthermore, infusions of specific receptor
antagonists help determine the neurochemical nature of the neuronal pathways involved
in mediating stimulation-evoked striatal dopamine release. To confirm that the observed
drug effects are not attributable to non-specific effects of the microinfusion procedure,
microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4) served as a control.

Post-Experiment Procedures
Upon the completion of each FPA session, the stimulation, recording, and infusion sites
are marked, either by lesioning or stain infusion. After euthanasia, the brains are
removed and properly stored until sectioning. Coronal sections are sliced in a cryostat
and observed under a light microscope to confirm that the placements of stimulating
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electrodes, recording electrodes, and drug infusion cannulae are within the anatomical
boundaries of the target site.
The mean change in dopamine oxidation current, corresponding to stimulationevoked dopamine efflux, is converted to mean dopamine concentration (µM) by postexperiment in vitro calibration of the carbon fiber electrode in solutions of dopamine (210 µM) using a flow injection system (Michael and Wightman, 1999). For each animal,
changes in stimulation-evoked dopamine concentration after infusion were expressed as
mean percent changes with respect to pre-infusion baseline responses (100%) and are
subsequently averaged across animals. The appropriate statistical tests are then
performed, either comparing between experimental groups or before and after drug
infusion.
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Chapter 5. Neural Pathways Mediating Striatal Dopamine Release following High
Frequency Stimulation: Relevance to DBS as a Treatment for Parkinson’s Disease

Deep brain stimulation (DBS) is an established interventive neurosurgical approach for
effectively treating the motor symptoms of Parkinson’s disease (Benabid, 2003; Krack et
al., 2003). The most common stimulation site for DBS as a treatment for Parkinson’s
disease is the subthalamic nucleus (STN); however, the pedunculopontine tegmental
nucleus (PPT) is emerging as a therapeutically beneficial target when stimulated by itself
or in combination with the STN (Stefani et al., 2007). Thus, the connectivity between
these two nuclei and the basal ganglia is the focus of the present paper. Despite the
acceptance of DBS as a therapeutic tool for treating parkinsonian motor symptoms,
which onset with at least 80% decrease in striatal dopamine content and 50% or greater
loss of dopaminergic neurons in the substantia nigra compacta (SNc) (Fearnley and Lees,
1991; Samii et al., 2004), the mechanism of action of DBS remains poorly understood
and debated in research. Because the therapeutic effects of DBS are similar to those of a
lesion, DBS has been thought to act by silencing neuronal activity at the site of
stimulation (Benazzouz et al., 1995; Lozano et al., 2002). However, emerging evidence
implicates additional mechanisms, which involve activation of local neuronal terminals at
the site of DBS that inhibit and/or excite efferent outputs. In turn, this has been
postulated to enhance efferent neurotransmission, which may ultimately normalize
activity within structures of the basal ganglia complex (Benabid, 2003; Lozano and
Eltahawy, 2004; McIntyre et al., 2004; Uc and Follett, 2007). Specifically, recent studies
in rodents have shown that electrical stimulation of the STN results in excitation of
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neurons in the STN (Garcia et al, 2003; Lee et al., 2007), increased activity in
dopaminergic neurons of the SNc (Lee et al., 2003, 2004), as well as enhanced dopamine
release in the striatum (Lee et al., 2006). These findings have led to the “dopamine
release” hypothesis which proposes that STN DBS improves motor symptoms related to
Parkinson’s disease, in part, by activating surviving nigrostriatal dopamine neurons and
subsequently increasing striatal dopamine release (Lee et al., 2009). DBS of the STN has
been shown to decrease or eliminate the need for levodopa (Molineuvo et al., 2000; Moro
et al., 1999) and is most effective in patients who have responded well to levodopa (Breit
et al., 2004). Thus, clinical findings support the dopamine release hypothesis by
suggesting endogenous dopamine production is required for DBS to be therapeutically
successful. Furthermore, DBS can generate dyskinesias resembling those seen when
excess levodopa is given (Frank et al., 2007).
STN DBS could elicit dopamine release in the striatum through activation of a
number of neural pathways. First, stimulation of the glutamatergic neurons that project
from the STN to the SNc have been shown to activate nigrostriatal dopaminergic neurons
directly (Meltzer et al., 1997). Second, stimulation of glutamatergic neurons of the STN
projecting to the PPT may indirectly activate nigrostriatal dopamine neurons via both
reciprocal excitatory innervation back to the STN which leads to subsequent SNc
activation by the aforementioned glutamatergic inputs (Lee et al., 2000) and/or by
activating excitatory cholinergic and glutamatergic PPT neuronal projections to the SNc
(Blaha and Winn, 1993; Forster and Blaha, 2003). Thirdly, DBS of the STN may
activate nigrostriatal dopamine neurons via direct stimulation of the dorsal portion of the
medial forebrain bundle (MFB) within the zona incereta. Therapeutic outcomes of DBS
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have suggested that the best symptom improvements result when stimulating the white
matter just dorsal to the STN (Saint-Cyr et al., 2002; Voges et al., 2002). DBS in this
region likely results in stimulation of dopaminergic axons within the MFB passing
directly from the SNc to the striatum. Thus, it is conceivable that DBS directly aimed at
the MFB may be superior to STN DBS in enhancing striatal dopamine release (Lee et al.,
2006). Therefore, the present study also conducted experiments designed to determine
the neuronal pathways involved in evoking striatal dopamine release via stimulation of
the MFB.
In regards to DBS of the PPT, the interconnectivity between the PPT and nuclei
within the basal ganglia complex allows the PPT to play a critical role in the modulation
of nigrostriatal dopaminergic activity (Forster and Blaha, 2003; Miller and Blaha, 2004;
Mena-Segovia et al., 2008), which may explain the findings from recent clinical trials
showing that DBS of the PPT is effective in ameliorating parkinsonian motor symptoms,
particularly gait and postural disabilities (Stefani et al., 2007). Thus, the present study
also investigated the relative influence of cholinergic and glutamatergic PPT projections
in eliciting striatal dopamine release. Previous work from our lab using in vivo
chronoamperometry has shown that PPT stimulation elicits striatal dopamine release, in
which dopamine release could be blocked by intra-SNc infusions of nicotinic and
muscarinic acetylcholine receptor (nAchR and mAchR, respectively), and ionotropic
glutamate receptor (iGluR) antagonists (Forster and Blaha, 2003). However, in addition
to direct excitatory inputs to SNc dopaminergic cells, as noted above, the PPT may also
indirectly activate these dopaminergic cells via cholinergic and glutamatergic projections
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to excitatory glutamatergic neurons in the STN that, in turn, innervate SNc dopaminergic
cells (Bevan and Bolam, 1995; Lee et al., 2000).
To-date no studies have systematically examined these candidate pathways as to
their relative involvement in mediating the effects of MFB, STN, or PPT DBS on striatal
dopamine release. Therefore, the present studies investigated these potential pathways in
vivo using fixed potential amperometry (FPA) with carbon fiber microelectrodes
positioned in the striatum to record striatal dopamine efflux evoked by DBS-like high
frequency electrical stimulation (HFS) of the MFB, STN, or PPT. By temporarily
blocking transmission through various nuclei via microinfusions of the local anaesthetic
lidocaine, we were able to determine whether HFS of the MFB, STN, or PPT evokes
striatal dopamine transmission via direct or indirect routes to the SNc and their relative
importance in mediating these effects. Furthermore, infusions of specific receptor
antagonists helped to uncover the neurochemical nature of the pathways that mediate
MFB, STN, and PPT stimulation-evoked striatal dopamine release.

Experimental Procedures
The following experiments were approved by the Institutional Animal Care and Use
Committee at the University of Memphis and conducted in accordance with the National
Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Efforts were
made to reduce the number of animals used and to minimize animal pain and discomfort.
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Animals and surgery
Seventy-six male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA), 8-11
weeks of age and weighing 20-27 g at the time of surgery, were used. Animals were
housed five per cage in a temperature controlled environment (21 + 1ºC) with a 12 h
light: 12 h dark cycle (lights on at 0600 h). Food and water were available ad libitum.
Mice were anesthetized with urethane (1.5 g/kg, i.p.) and mounted in a stereotaxic frame
(David Kopf Instruments, Tujunga, CA, USA) within a mouse head-holder adaptor
(Stoelting, Wood Dale, IL, USA), ensuring the skull was flat. Body temperature was
maintained at 36 ± 0.5°C with a temperature-regulated heating pad (TC-1000; CWE Inc.,
New York, NY, USA). Determined from the mouse atlas of Paxinos and Franklin
(2001), stereotaxic coordinates (AP from bregma, ML from midline, and DV from dura,
all in mm) for each target site were as follows: striatum: AP 1.4, ML +1.4, DV -2.5;
MFB: AP -2.0, ML +1.1, DV -4.0; STN: AP -2.0, ML +1.6, DV -4.0; SNc: AP -3.1, ML
+1.5, DV -3.8; PPT: AP -4.7, ML +1.25, DV -2.7). In each mouse a concentric bipolar
stimulating electrode (SNE-100; Rhodes Medical Co., CA, USA) was implanted into the
left MFB, STN, or PPT of each mouse. A 31 g stainless-steel guide infusion cannula was
implanted into the left SNc, STN, or PPT with the tip of the guide cannula positioned 2
mm above site. An Ag/AgCl reference and stainless-steel auxiliary electrode
combination was placed in surface contact with contralateral cortical tissue
approximately 2.0 mm posterior to bregma, and a carbon fiber recording microelectrode
with an active recording surface of 250 μm (length) by 10 μm (o.d.) (Thornel Type P,
Union Carbide, Pittsburgh, PA, USA) was then implanted into the left striatum.
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FPA and electrical stimulation
All amperometric recordings were made within a Faraday cage to increase the signal to
noise ratio (Forster and Blaha, 2003). A fixed potential (+0.8 V) was applied to the
recording electrode, and oxidation current was monitored continuously (10K
samples/sec) with an electrometer filtered at 50 Hz. Approximately 10 min following
implantation of the recording electrode, a series of 0.5 ms duration cathodal monophasic
current pulses (20 pulses at 50 Hz applied every 30 sec over a 1 hr recording period) was
delivered to the stimulating electrode via an optical isolator and programmable pulse
generator (Iso-Flex/Master-8; AMPI, Jerusalem, Israel). Intensity levels were set at 800
µAmps in the MFB and PPT and 400 µAmps in the STN as determined by preliminary
studies to be optimal for each target site. Intensity levels were also lower in the STN in an
attempt to conclusively limit the stimulation region to the STN. FPA coupled with
carbon fiber microelectrodes has been confirmed as a valid technique for real-time
monitoring of changes in striatal dopamine oxidation current evoked by brief electrical
stimulation of afferent inputs to midbrain dopamine neurons (Dugast et al., 1994; Forster
and Blaha, 2003; Lester et al., 2008).

Drug microinfusions
Microinfusions were performed by first backloading the drug into a fibreglass cannula
(80 m o.d., Polymicro Tech. Inc., AZ, USA) connected via PE10 tubing to a 5 l
microsyringe (Scientific Glass Engineering Inc., Austin, TX, USA) mounted on a
microinfusion pump (Stoelting, Wood Dale, IL, USA). After a 10 min electrical
stimulation baseline recording period, the cannula was inserted 2 mm beyond the tip of
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the implanted guide cannula, and 1.0 µl infusions were made over a 1.5 min period.
Infusions of the local anesthetic lidocaine (4%) were performed to temporarily block
axonal transmission to or from the infusion sites (Blaha et al., 1997; Floresco et al.,
1998). By temporarily blocking transmission through the SNc, STN, or PPT, we were
able to determine whether HFS of the MFB, STN, or PPT evokes striatal dopamine
transmission via direct or indirect routes to the SNc. Furthermore, in order to assess the
relative contributions of GluRs and AchRs in the SNc and STN in mediating stimulationevoked striatal dopamine release, MFB, STN, or PPT-evoked striatal dopamine release
was monitored in separate groups of mice before and during intra-SNc or STN infusions
of the iGluR antagonist kynurenate (1 µg), the metabotropic GluR (mGluR) antagonist
(+)-methyl-4-carboxyphenylglycine (MCPG; 1 µg), the mAchR antagonist scopolamine
(10 µg), the nAchR antagonist mecamylamine (1 µg), or a combination of these drugs.
To confirm that observed drug effects were not attributable to non-specific effects of the
microinfusion procedure, microinfusions of 1.0 µl of sterile phosphate-buffered saline
(PBS, pH~7.4) were also performed. See Table 1 for the complete list of experimental
groups. The microinfusion cannula was left in place over the duration of the experiment.
All drugs were prepared immediately before use at doses determined by preliminary
studies in this laboratory.

39

Table 1. Drugs used to assess the contributions of cholinergic and glutamatergic
projections on stimulation-evoked changes in striatal dopamine concentrations.
Stimulation
Site

Infusion
Site

Drug

Target receptors

% Change
from baseline

MFB

SNc

PBS

–

- 2% ± 1

MFB

SNc

Lidocaine

axonal

+ 62% ± 12

MFB

SNc

Kynurenate

iGluRs

- 3% ± 4

MFB

PPT

PBS

–

- 3% ± 1

MFB

PPT

Lidocaine

axonal

- 4% ± 4

STN

SNc

PBS

–

- 4% ± 2

STN

SNc

Lidocaine

axonal

- 84% ± 3

STN

PPT

PBS

–

- 1% ± 3

STN

PPT

Lidocaine

axonal

- 46% ± 6

STN

SNc

Kynurenate

iGluRs

- 46% ± 4

STN

SNc

MCPG

mGluRs

- 3% ± 1

STN

SNc

Scopolamine

mAchRs

- 28% ± 5

STN

SNc

Mecamylamine

nAchRs

- 28% ± 5

PPT

SNc

PBS

–

- 2% ± 2

PPT

SNc

Lidocaine

axonal

- 90% ± 3

PPT

STN

PBS

–

- 5% ± 3

PPT

STN

Lidocaine

axonal

- 50% ± 8

PPT

STN

Kynurenate + MCPG

iGluRs + mGluRs

- 23% ± 6

PPT

STN

Scopolamine +
mecamylamine

mAchRs + nAchRs

- 26% ± 3
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Data collation and statistical analysis
MFB, STN, or PPT stimulation-evoked dopamine efflux were quantified by extraction of
data points occurring within the range of 0.25 sec pre- and 2.0 sec post-stimulation from
the recorded oxidation current in the striatum at 30 sec intervals over the course of the
recording period. The mean change in dopamine oxidation current, corresponding to
stimulation-evoked dopamine efflux, was converted to a mean dopamine concentration
(µM) by post-experiment in vitro calibration of the carbon fiber electrode in solutions of
dopamine (2-10 µM) using a flow injection system (Michael and Wightman, 1999). For
each animal, changes in stimulation-evoked dopamine concentration after infusion were
expressed as mean percent changes with respect to pre-infusion baseline responses
(100%). Mean peak levels in dopamine concentration following the infusion were
statistically compared to pre-infusion baseline responses using paired two-tailed t-tests
with the alpha level set at 0.05.

Histology
Upon the completion of each experimental session, an iron deposit was made in the
stimulation and recording site by passing direct anodic current (100 μA and 1 mA,
respectively) for 10 sec through the stimulating and recording electrodes, and 1.0 µl
cresyl violet stain was infused into the cannula site. Mice were then euthanized with a
0.25 ml intracardial injection of urethane (0.345 g/ml). Brains were removed, immersed
overnight in 10% buffered formalin containing 0.1% potassium ferricyanide, and then
stored in 30% sucrose/ 10% formalin solution until sectioning. After fixation, 30 µm
coronal sections were sliced in a cryostat at -30°C, with a Prussian blue spot resulting
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from a redox reaction of the ferricyanide marking the stimulation site. Placements of
stimulating electrodes, recording electrodes, and drug infusion cannulae were determined
under a light microscope and recorded on representative coronal diagrams (Paxinos and
Franklin, 2001).

Chemicals
Urethane, lidocaine, kynurenate, MCPG, scopolamine, and mecamylamine were obtained
from Sigma-Aldrich Chemical Co. (St Louis, MO, USA). All chemicals, with the
exception of urethane (distilled water), were dissolved in sterile PBS (pH~7.4).

Results
Stereotaxic placements of infusion cannulae, recording and stimulating electrodes
Recording electrode placements (n = 56) were confined to the striatum (range in mm:
1.34 to 1.54 anterior to bregma, 1.30 to 1.60 lateral to midline, and 2.40 to 2.70 ventral to
dura; Fig. 1A). Stimulating electrode tips (n = 20) were localized within the MFB (range
in mm: 1.94 to 2.18 mm posterior to bregma, 1.00 to 1.20 mm lateral to midline, and 3.80
to 4.10 mm ventral to dura; Fig. 1B). Stimulating electrode tips (n = 28) and infusion
cannula tip placements (n = 16) were accurately positioned within the STN (range in mm:
1.94 to 2.18 posterior to bregma, 1.50 to 1.70 lateral to midline, and 3.90 to 4.20 ventral
to dura; Fig. 1B), and infusion cannula tip placements (n = 28) were localized within the
SNc (range in mm: 2.92 to 3.16 posterior to bregma, 1.40 to 1.60 lateral to midline, and
3.60 to 3.90 ventral to dura; Fig. 1C). The tips of stimulating electrodes (n = 24) and
infusion cannula (n = 8) were confined within the PPT (range in mm: 0.39 to 0.63
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posterior to lambda, 1.15 to 1.40 lateral to midline, and 2.60 to 2.90 ventral to dura; Fig.
1D).

Fig. 1. Representative coronal sections of the mouse brain (adapted from the atlas of
Paxinos and Franklin, 2001), with dark gray shaded areas indicating the placements of
carbon fiber recording electrodes in the striatum (A), stimulating electrodes or drug
infusion cannulae in the medial forebrain bundle (MFB) (B), subthalamic nucleus (STN)
(B), substantia nigra compacta (SNc) (C), or pedunculopontine tegmental nucleus (PPT)
(D). Numbers correspond to mm from bregma.
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Effects of intra-SNc or PPT lidocaine or SNc GluR blockade on MFB stimulation-evoked
dopamine efflux
With respect to pre-infusion baseline levels, MFB stimulation-evoked striatal dopamine
efflux was not significantly altered at 5 min following PBS infusion into the SNc (n = 4;
98.1% ± 0.8, p = 0.09; Fig. 2A and C) or PPT (n = 4; 97.4% ± 1.1, p = 0.10; Fig. 2B and
D). Intra-SNc infusion of lidocaine significantly increased MFB stimulation-evoked
striatal dopamine levels from pre-infusion baseline levels (n = 4; 161.6% ± 12.4, p =
0.03; Fig. 2A and C) with the peak increase occurring 5 min post-infusion. However,
lidocaine infused into the PPT did not significantly alter MFB stimulation-evoked
dopamine efflux in the striatum assessed at 5 min following infusion (n = 4; 95.8% ± 3.9,
p = 0.35; Fig. 2B and D). Infusion of the iGluR antagonist kynurenate into the SNc also
had no significant affect on MFB stimulation-evoked striatal dopamine efflux assessed at
5 min following infusion (n = 4; 96.8% ± 3.9, p = 0.472; Fig. 2A and C).
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Fig. 2. Mean amperometric recordings of dopamine release in the striatum evoked by
electrical stimulation of the dorsal portion of the medial forebrain bundle (A and B) and
corresponding mean peak percentages (C and D). Profiles illustrate mean peak effects in
response to substantia nigra compacta (SNc) (A) or pedunculopontine tegmental nucleus
(PPT) (B) microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4) or lidocaine
(lid) or the ionotropic glutamate receptor antagonist kynurenate (kyn). Time zero
indicates the start of the train of 20 pulses at 50 Hz. * Significant change in striatal
dopamine concentration after infusion compared to pre-infusion baseline responses
(100%).
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Effects of intra-SNc or PPT lidocaine on STN stimulation-evoked dopamine efflux
With respect to pre-infusion baseline levels, STN stimulation-evoked striatal dopamine
efflux was not significantly altered at 5 min following PBS infusion into the SNc (n = 4;
96.2% ± 1.7, p = 0.11; Fig. 3A and C) or PPT (n = 4; 99.5% ± 3.1, p = 0.87; Fig. 3B and
D). STN stimulation-evoked striatal dopamine efflux was significantly attenuated by
lidocaine (4%) infused into either the SNc (n = 4; 15.9% ± 3.9, p < 0.01; Fig. 3A and C)
or the PPT (n = 4; 54.2% ± 6.4, p = 0.02; Fig. 3B and D) compared to pre-infusion
baseline levels, with the peak decrease occurring 5 min post-infusion.

Fig. 3. Mean amperometric recordings of dopamine release in the striatum evoked by
electrical stimulation of the subthalamic nucleus (A and B) and corresponding mean peak
percentages (C and D). Profiles illustrate mean peak effects in response to substantia
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nigra compacta (SNc) (A) or pedunculopontine tegmental nucleus (PPT) (B)
microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4) or lidocaine (lid).
Time zero indicates the start of the train of 20 pulses at 50 Hz. * Significant change in
striatal dopamine concentration after infusion compared to pre-infusion baseline
responses (100%).

Effects of SNc GluR or AchR blockade on STN stimulation-evoked dopamine efflux
With respect to pre-infusion baseline levels, intra-SNc infusion of the iGluR antagonist
kynurenate (1 µg) significantly attenuated STN stimulation-evoked striatal dopamine
levels (n = 4; 54.1% ± 3.0, p < 0.01; Fig. 4A and B) with the peak decrease occurring 5
min post-infusion; however, intra-SNc infusion of the mGluR antagonist MCPG (1 µg)
had no significant effect on STN stimulation-evoked striatal dopamine levels (n = 4;
97.1% ± 1.1, p = 0.09; Fig. 4A and B). STN stimulation-evoked striatal dopamine was
also significantly reduced by intra-SNc infusion of the muscarinic AchR antagonist
scopolamine (10 µg; n = 4; 72.2% ± 4.6, p < 0.01; Fig. 4A and B) or the nicotinic AchR
antagonist mecamylamine (1 µg; n = 4; 71.8% ± 4.8, p = 0.01; Fig. 4A and B), with the
peak decrease occurring 5 min after infusion of each drug.
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Fig. 4. Mean amperometric recordings of dopamine release in the striatum evoked by
electrical stimulation of the subthalamic nucleus (A) and corresponding mean peak
percentages (B). Profiles illustrate mean peak effects in response to substantia nigra
compacta (SNc) microinfusions of the ionotropic glutamate receptor antagonist
kynurenate (kyn), the metabotropic glutamate receptor antagonist (+)-methyl-4carboxyphenylglycine (MCPG), the muscarinic acetylcholine receptor antagonist
scopolamine (scop), or the nicotinic acetylcholine receptor antagonist mecamylamine
(mec). Time zero indicates the start of the train of 20 pulses at 50 Hz. * Significant
change in striatal dopamine concentration after infusion compared to pre-infusion
baseline responses (100%).
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Effects of intra-SNc or STN lidocaine on PPT stimulation-evoked dopamine efflux
With respect to pre-infusion baseline levels, PPT stimulation-evoked striatal dopamine
efflux was not significantly altered at 5 min following PBS infusion into the SNc (n = 4;
98.2% ± 2.2, p = 0.50; Fig. 5A and C) or STN (n = 4; 95.7% ± 3.3, p = 0.28; Fig. 5B and
D). PPT stimulation-evoked dopamine in the striatum was completely abolished
following intra-SNc lidocaine (4%) infusion (n = 4; 9.9% ± 2.6, p < 0.01; Fig. 5A and C)
and significantly, but less dramatically, reduced following intra-STN lidocaine infusion
(n = 4; 50.0% ± 7.7, p < 0.01; Fig. 5B and D), with the peak decrease at each site
occurring 5 min post-infusion.

Fig. 5. Mean amperometric recordings of dopamine release in the striatum evoked by
electrical stimulation of the pedunculopontine tegmental nucleus (A and B) and
corresponding mean peak percentages (C and D). Profiles illustrate mean peak effects in
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response to substantia nigra compacta (SNc) (A) or subthalamic nucleus (STN) (B)
microinfusions of sterile phosphate-buffered saline (PBS, pH~7.4), lidocaine (lid), a
combination of the ionotropic glutamate receptor antagonist kynurenate (kyn) with the
metabotropic glutamate receptor antagonist (+)-methyl-4-carboxyphenylglycine (MCPG),
or a combination of the nicotinic acetylcholine receptor antagonist mecamylamine (mec)
and the muscarinic acetylcholine receptor antagonist scopolamine (scop). Time zero
indicates the start of the train of 20 pulses at 50 Hz. * Significant change in striatal
dopamine concentration after infusion compared to pre-infusion baseline responses
(100%).

Effects of STN GluR or AchR blockade on PPT stimulation-evoked dopamine efflux
With respect to pre-infusion baseline levels, infusion of a combination of the iGluR
antagonist kynurenate (1 µg) and the mGluR antagonist MCPG (1 µg) into the STN
significantly attenuated PPT stimulation-evoked dopamine efflux in the striatum (n = 4;
77.5% ± 6.2, p = 0.03; Fig. 5B and D) with the peak decrease occurring 5 min postinfusion. PPT stimulation-evoked striatal dopamine was also significantly reduced by
blockade of STN AchRs (n = 4; 74.2% ± 3.4, p < 0.01; Fig. 5B and D) via infusion of a
combination of the mAchR antagonist scopolamine (10 µg) and the nAchR antagonist
mecamylamine (1 µg), with the peak decrease occurring 5 min post-infusion.
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Discussion
As measured by in vivo FPA, stimulation of either the MFB, STN, or PPT elicits
dopamine release in the dorsal striatum. STN stimulation-evoked striatal dopamine
release was markedly attenuated by inactivation of either the SNc or the PPT, and PPT
stimulation-evoked dopamine release in the striatum was significantly reduced following
inactivation of either the SNc or the STN. Therefore, neural interactions between these
nuclei are likely involved in the underlying mechanisms of DBS as a treatment for the
motor symptoms of Parkinson’s disease. The present findings provide a glimpse at the
relative significance of the glutamatergic and cholinergic connections between the SNc,
STN, and PPT in regards to striatal dopamine neurotransmission.

Neuronal pathways mediating striatal dopamine release following MFB stimulation
Lee et al. (2006) used a monoclonal antibody to TH to demononstrate in rats that the
axons of ascending dopamine neurons from the SNc align closely along the dorsal
surface of the STN with some fibers potentially passing through the nucleus itself. A
similar pattern of TH staining of catecholaminergic neurons has been shown in both
monkeys and humans (Lee et al., 2005). Thus, it is conceivable that clinical DBS of the
STN is activating these axons of the MFB due to the close proximity and that HFS of the
MFB may optimally enhance dopamine transmission in the basal ganglia (Lee et al.,
2006). The present findings suggest that MFB stimulation is mediated predominately by
activation of ascending SNc dopamine neurons, as lidocaine infusions into the SNc did
not reduce MFB-evoked striatal dopamine release. Previous studies have shown that
pharmacological denervation of dopamine axonal transmission promotes a rapid
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compensatory mechanism that dramatically enhances synthesis and storage of dopamine
in terminal vesicles (Brown et al., 1991). These findings are consistent with our
observation of an enhancement in MFB stimulation-evoked striatal dopamine release
following lidocaine inactivation of the SNc. The present results show that stimulation of
the MFB is not dependent upon SNc iGluRs, as kynurenate infused into the SNc had no
effect on MFB-evoked dopamine, again suggesting that MFB stimulation is mediated
predominately by activation of ascending SNc dopamine neurons rather than
neurochemical activities within the SNc. Altogether, these data may help to explain the
clinical improvements in motor symptoms of Parkinson’s patients following stimulation
of the border and white matter dorsal to the STN (Herzog et al., 2004; Saint-Cyr et al.,
2002; Voges et al., 2002).

Neuronal pathways mediating striatal dopamine release following STN stimulation
The present study examined several neuronal circuits in the mid- and hindbrain by which
clinical DBS of the STN could increase striatal dopamine transmission. Stimulation of
the STN has been shown to alter neuronal activity within the SNc of rodents generating
initial transient inhibitory (via activation of GABAergic interneurons in the SN reticulata)
and more prolonged excitatory (via direct activation of dopaminergic neurons in the SNc)
postsynaptic potentials (Lee et al., 2004), leading to increased firing of SNc neurons
(Hammond et al., 1978; Iribe et al., 1999; Benazzou et al., 2000). Changes in STN
activity have also been shown to significantly affect discharge patterns of SNc neurons
and striatal dopamine release in primates. Shimo and Wichmann (2009) concluded that
increases in the firing rate of SNc neurons following intra-STN injections of carbachol,
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and decreases in the firing rate of SNc neurons after intra-STN injections of muscimol,
may have resulted from changes in activity along the connections between the STN and
SNc via an excitatory glutamatergic pathway well documented in rodent research
(Hammond et al., 1978; Kita and Kitai, 1987; Smith and Parent, 1988). However, the
monosynaptic pathway between the STN and SNc has been shown to be relatively sparse
in primates compared to rodents (Smith et al., 1990; Sato et al., 2000). Therefore, the
observed changes in SNc discharge patterns in primates may have been mediated
primarily by excitatory SNc afferents from the PPT (Futami et al., 1995; Charara et al.,
1996). The STN and PPT are reciprocally interconnected with excitatory projections
(Futami et al., 1995; Lee et al., 2000), which have been shown to be both cholinergic and
glutamatergic from the PPT to the STN (Moon-Edley and Graybiel, 1983; Oakman et al.,
1999). In vivo electrochemical studies in rodents have previously shown that electrical
and chemical stimulation of the PPT enhances dopamine efflux in the striatum (Forster
and Blaha, 2003; Miller and Blaha, 2004); thus, it is highly probable that stimulation of
the STN in primates may be increasing discharge patterns of SNc dopaminergic neurons
to elicit striatal dopamine release indirectly through STN activation of the PPT.
The present results confirm that STN stimulation is dependent on activities of
both the SNc and PPT, as inactivation of either of these nuclei decreased STN-evoked
striatal dopamine efflux by 84.1% and 45.8%, respectively, compared to pre-infusion
baseline responses. Thus, these findings suggest that HFS of the STN works by
activating the SNc directly via excitatory STN-SNc projections and indirectly via
excitatory STN-PPT projections that, in turn, provide excitatory PPT inputs to SNc
dopamine cells. However, these findings cannot distinguish the extent to which STN
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stimulation is activating dopamine cells in the SNc via reciprocal excitatory innervation
between the STN and PPT. Future experiments incorporating intra-STN infusions of
selective glutamate and acetylcholine receptor antagonists would address this issue. In
addition, STN stimulation-evoked striatal dopamine release was significantly diminished
by inactivation of the SNc; however, it was not completely abolished. This is not
surprising considering the relatively wide medial to lateral distribution of dopamine cell
bodies in the midbrain comprising the SNc (see Fig. 1C), such that a single infusion of
drug into the SNc likely fails to inactivate all of these cells. Thus, the small remaining
response (15.9%) can be attributed either to incomplete drug inactivation of the SNc.
Alternatively, unavoidable stimulation of some of the dopamine axons within the medial
forebrain bundle that project immediately dorsal to STN on their way to the striatum may
also have contributed to the response following intra-SNc lidocaine inactivation. This
observation would support the notion that STN DBS may act by directly stimulating SNc
dopamine axons passing near or through the STN (Lee et al., 2006).
The STN and PPT are the only subcortical nuclei in the basal ganglia complex
whose glutamate-containing neurons directly innervate nigrostriatal dopaminergic
neurons (Kitai et al., 1999; Overton and Clark, 1997). Stimulation of the STN has been
shown to alter neuronal activity within the substantia nigra of rodents resulting in
elevated glutamate release in the SNc (Windels et al., 2000). Glutamate release in the
SNc activates dopamine neurons that project to the striatum. The present results show
that STN stimulation is dependent upon iGLuRs, but not mGluRs, in the SNc as intraSNc kynurenate significantly decreased STN-evoked striatal dopamine release (54.1%)
while intra-SNc MCPG had no effect. These findings are consistent with our previous
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findings and others (Balon et al., 2003; Forster and Blaha, 2003; Lavoute et al., 2006).
The remaining STN stimulation-evoked striatal dopamine release (45.9%) following
intra-SNc kynurenate infusion can be attributed to a major extent to excitatory
cholinergic SNc inputs from the PPT. However, as mentioned, it cannot be completely
discounted that a small portion of the signal may have been due to unavoidable
stimulation of a small number of dopamine axons immediately dorsal to the STN within
the medial forebrain bundle. Intra-SNc infusions of scopolamine or mecamylamine
decreased STN-evoked striatal dopamine release by 27.8% and 28.2%, respectively.
Accordingly, these results suggest that cholinergic projections from the PPT to the SNc
mediate roughly half of the STN stimulation-evoked dopamine release in the striatum. In
sum, the present data confirms the significance of the PPT in STN stimulation-evoked
striatal dopamine release and suggest that glutamatergic projections (acting on iGluRs in
the SNc) and cholinergic projections (acting on mAchRs and nAchRs in the SNc)
mediate approximately half of the striatal dopamine release following STN stimulation.

Neuronal pathways mediating striatal dopamine release following PPT stimulation
Excitatory glutamatergic and cholinergic inputs from the PPT directly project to
dopamine-containing cell bodies in the SNc (Blaha and Winn, 1993; Forster and Blaha,
2003; Moon-Edley and Graybiel, 1983; Oakman et al., 1999). Our previous work using
in vivo chronoamperometry to measure basal changes in dopamine release has shown that
PPT stimulation elicits an initial transient increase in striatal dopamine release, in which
this rapid increase in dopamine release could be blocked by a combination of intra-SNc
infusions of nAchR and iGluR antagonists. This transient stimulation time-locked
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increase was followed by a delayed, prolonged increase in striatal basal dopamine release
that could be selectively blocked by mAchR antagonists infused into the SNc (Forster
and Blaha, 2003). However, electrical stimulation of the PPT has also been shown to
activate STN neurons via cholinergic and glutamatergic projections (Woolf and Butcher,
1986; Hammond et al., 1983). Therefore, in addition to direct cholinergic activational
inputs to SNc dopaminergic cells, the PPT may also enhance striatal dopamine release via
indirect PPT glutamatergic and cholinergic inputs to STN glutamatergic neurons that, in
turn, innervate directly dopamine-containing cells in the SNc (Bevan and Bolam, 1995;
Lee et al., 2000). The present results show that PPT stimulation-evoked striatal
dopamine release is significantly dependent on activities of the SNc and STN, as
inactivation of the SNc and STN lead to decreases in PPT-evoked striatal dopamine
efflux of 90.1% and 50.0%, respectively, compared to pre-infusion baseline responses.
Thus, these findings suggest that clinical DBS of the PPT may involve activation of the
SNc directly via excitatory PPT-SNc projections and indirectly via excitatory PPT-STN
projections that, in turn, provide excitatory inputs to SNc dopamine cells. However,
these findings cannot distinguish the extent to which PPT stimulation is activating
dopamine cells in the SNc via reciprocal excitatory innervation between the STN to the
PPT. Future experiments incorporating intra-PPT infusions of selective GluR antagonists
would address this issue.
The present study further examined the excitatory glutamatergic and cholinergic
pathway from the PPT to the STN and found that PPT-evoked striatal dopamine release is
dependent upon both GluRs and AchRs in the STN, as intra-STN GluR antagonists or
AchR antagonists both significantly decreased PPT-evoked striatal dopamine release by
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22.5% or 25.8%, respectively. Together, the present data confirms the significance of the
SNc, as well as the STN, in PPT stimulation-evoked striatal dopamine release and
suggests that combined glutamatergic and cholinergic projections from the PPT to the
STN are mediate approximately half of PPT-evoked dopamine release in the striatum.

Conclusions
The present study shows that electrical stimulation of the MFB, STN, or PPT elicits
dopamine release in the striatum. MFB stimulation evokes striatal dopamine through
direct stimulation of dopamine axons and is independent of neurochemical activity within
the SNc and PPT, while STN or PPT stimulation elicits striatal dopamine through several
neural routes. The relative contributions of the direct and indirect projections to the SNc
that are involved in mediating STN or PPT stimulation-evoked dopamine release are
summarized in Fig. 6A and B. STN-evoked dopamine release in the striatum is almost
fully dependent upon (84.1%) activation of dopamine cells in the SNc, while also
partially dependent upon projections from the PPT (45.9%). Fig. 6A also illustrates the
relative involvement of SNc iGluRs (45.9%) and mAchRs and nAchRs (27.8% and
28.2%, respectively) in STN-evoked striatal dopamine release. PPT-evoked striatal
dopamine release was highly dependent upon activation of dopamine cells in the SNc
(90.1%), and partially dependent upon activation of STN cells that project to the SNc
(50.0%), equivalent to the relative involvement of STN GluRs or AchRs (22.5% +
25.8%).
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Fig. 6. Summary of relative contributions of neuronal projections mediating subthalamic
nucleus (STN) (A) or pedunculopontine tegmental nucleus (PPT) (B) stimulation-evoked
dopamine release in the striatum (stri). ACh: acetylcholine; Glu: glutamate; m/nAchR:
muscarinic/nicotinic acetylcholine receptor; iGluR: ionotropic glutamate receptor; SNc:
substantia nigra compacta.

In relation to DBS as a treatment for Parkinson’s disease, these findings support
research indicating that DBS of the STN, as well as the PPT, provides therapeutic
benefits due to increased extracellular levels of dopamine in the striatum (Lee et al.,
2009). Although these studies were conducted in intact animals, future experiments
using the present neurochemical recording procedures in 6-OHDA lesioned mice would
provide knowledge of the involvement of these pathways in an animal model of
Parkinson’s disease. Another intriguing future experiment could be monitoring
dopamine concentrations while stimulating the STN and PPT simultaneously, as clinical
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studies have shown combined STN and PPT DBS to be more therapeutically efficacious
than DBS of the STN or PPT alone on certain symptoms, such as the control of axial
motor impairments (Stefani et al., 2007). Understanding the underlying mechanisms of
DBS of the STN and the interconnected PPT could lead to improvements in stimulation
locations and parameters, which may prove invaluable in improving DBS procedures and
enhancing its clinical efficacy for the treatment of Parkinson’s disease.
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Chapter 6. Substantia Nigra Compacta Glutamate Receptors Modulate
Dopamine Release in the Striatum

The nigrostriatal dopamine pathway, comprised of dopamine-containing neurons in the
substantia nigra compacta (SNc) and their projections to the striatum, is integral in motor
functioning, including the selection and initiation of contextually appropriate motor
patterns (Hauber, 1998; Redgrave et al., 1999). The dopaminergic neurons of the SNc
degenerate in Parkinson’s disease, leading to reduced dopamine levels in the striatum
and, subsequently, clinical symptoms such as bradykinesia, tremor, and rigidity (Fearnley
and Lees, 1991; Olanow and Tatton, 1999). Identifying receptors that modulate the
activity of dopamine neurons in the SNc may help in the development of novel
therapeutic strategies for treating the symptoms of Parkinson’s disease and perhaps even
slowing the progression of the disease. The subthalamic nucleus (STN) and the
pedunculopontine tegmental nucleus (PPT) provide significant glutamatergic excitatory
inputs to the SNc, which induce burst firing of SNc dopamine neurons resulting in
sustained release of dopamine in the striatum (Grillner and Mercuri, 2002; Kitai et al,
1999; Overton and Clark, 1997). Glutamatergic input to the SNc has received a great
deal of attention based on findings that suggest overactivity of STN glutamatergic
projections in Parkinson’s disease and the potential contributory role of long-lasting
glutamate receptor stimulation in the degeneration of dopaminergic neurons (Rodriguez
et al., 1998). The present study expands on the involvement of these projections in
Parkinson’s disease by focusing on their modulatory control of dopamine release in the
striatum.
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Previous studies have shown that the effects of glutamate in the SNc are mediated
by ionotropic glutamate receptors (iGluRs), which activate ion-gated channels, and
metabotropic glutamate receptors (mGluRs), which activate slow and more complex
effects mediated by G-coupled protein secondary messenger systems (Chatha et al, 2000;
Valenti et al, 2005). Three iGluR subclasses have been identified based on their
definitive agonist and include N-methyl-D-aspartic acid (NMDA), -amino-3-hydroxyl5-methyl-4-isoxazole-propionate (AMPA), and kainate, with the latter 2 sometimes
collectively referred to as non-NMDA receptors (Hollmann and Heinemann, 1994). The
relative contribution of these glutamate receptor subtypes in the SNc in mediating STN
glutamatergic activation of fast phasic activity of the nigrostriatal dopamine system
remains largely unknown. Therefore, the present study investigated the extent to which
each of these GluR subtypes is involved in mediating striatal dopamine release by
infusing NMDA, AMPA/kainate, and mGluR antagonists into the SNc while recording
STN stimulation-evoked dopamine efflux in the striatum using in vivo fixed potential
amperometry with carbon fiber microelectrodes.

Experimental procedures
All experiments were approved by the Institutional Animal Care and Use Committee at
the University of Memphis and conducted in accordance with the NIH Guidelines for the
Care and Use of Laboratory Animals. Efforts were made to reduce the number of
animals used and to minimize animal pain and discomfort.
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Animals and surgery
Sixteen male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA), 8-11 weeks
of age and weighing 20-27 g at the time of surgery, were used. Mice were housed four
per cage at 21 ± 1ºC with a 12 h light: 12 h dark cycle (lights on at 0600 h). Food and
water were available ad libitum. Mice were anesthetized with urethane (1.5 g/kg, i.p.)
and mounted in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA) with a
mouse head-holder adaptor (Stoelting, Wood Dale, IL, USA). A temperature-regulated
heating pad (TC-1000; CWE Inc., New York, NY, USA) maintained body temperature at
36 ± 0.5°C. All stereotaxic coordinates (AP from bregma, ML from midline, and DV
from dura, in mm) were determined from the mouse atlas of Paxinos and Franklin (2001).
In each mouse, a concentric bipolar stimulating electrode (SNE-100; Rhodes Medical
Co., CA, USA) was implanted into the left STN (coordinates: AP -2.0, ML +1.6, DV 4.0). A 31 g stainless-steel guide infusion cannula was implanted into the left SNc, with
the guide cannula tip 2 mm above site (coordinates: AP -3.1, ML +1.5, DV -3.8). An
Ag/AgCl reference and stainless-steel auxiliary electrode combination was placed on
contralateral cortical tissue approximately 2.0 mm posterior to bregma, and a carbon fiber
recording electrode (250 μm length x 10 μm o.d.; Thornel Type P, Union Carbide,
Pittsburgh, PA, USA) was then implanted into the left striatum (coordinates: AP 1.4,
ML +1.4, DV -2.5).

Fixed potential amperometry and electrical stimulation
Amperometric recordings in a Faraday cage consisted of applying a fixed potential (+0.8
V) to the recording electrode and monitoring dopamine oxidation current continuously
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(10K samples/sec) with an electrometer filtered at 50 Hz. Approximately 10 min
following implantation of the electrodes, a series of 0.5 ms duration cathodal monophasic
current pulses (20 pulses at 50 Hz applied every 30 sec at 800 µAmps) was delivered to
the stimulating electrode via an optical isolator and programmable pulse generator (IsoFlex/Master-8; AMPI, Jerusalem, Israel). Fixed potential amperometry with carbon fiber
electrodes has been confirmed as a valid technique for real-time monitoring of changes in
striatal dopamine oxidation current evoked by electrical stimulation of afferent inputs to
midbrain dopamine neurons (Dugast et al., 1994; Forster and Blaha, 2003; Lester et al.,
2008).

Drug microinfusions
Intra-SNc infusions were performed by backloading each drug into a fibreglass cannula
(80 m o.d., Polymicro Tech. Inc., AZ, USA) connected via PE10 tubing to a 5 l
microsyringe (Scientific Glass Engineering Inc., Austin, TX, USA) mounted on a
microinfusion pump (Stoelting, Wood Dale, IL, USA). After a 10 min baseline recording
period, the cannula was inserted 2 mm beyond the guide cannula tip, and 1.0 µl infusions
were made over a 1.5 min period. Separate groups of mice received intra-SNc infusions
of the following drugs: the mGluR antagonist (+)-α-methyl-4-carboxyphenylglycine
(MCPG) (2.0 µg), the NMDA receptor antagonist (±)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) (1.0 µg), and the AMPA/kainate receptor antagonist 6cyano-7-1fitroquinoxaline-2,3-dione (CNQX) (0.2 µg). Drugs were prepared
immediately before use at doses determined by preliminary studies in this laboratory.
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Separate phosphate-buffered saline (PBS, pH~7.4) infusions served as drug effect
controls.

Data collation and statistical analysis
STN stimulation-evoked dopamine efflux were quantified by extraction of data points
occurring within the range of 0.25 sec pre- and 2.0 sec post-stimulation at 30 sec intervals
from the recorded oxidation current. Mean changes in striatal dopamine oxidation
current, corresponding to STN stimulation-evoked dopamine efflux, were converted to
mean dopamine concentrations (µM) by post-experiment in vitro calibration of the
carbon fiber electrode in solutions of dopamine (2-10 µM) using a flow injection system
(Michael and Wightman, 1999). For each animal, changes in stimulation-evoked
dopamine concentration after infusion were expressed as mean percent changes with
respect to pre-infusion baseline responses (100%). Mean peak levels in dopamine
concentration following the infusion were statistically compared to pre-infusion baseline
responses using paired two-tailed t-tests. In order to compare the relative contributions of
NMDA and AMPA/kainate SNc receptors, mean peak percentage changes in dopamine
concentration were compared between the mice receiving intra-SNc infusion of CPP and
those receiving intra-SNc CNQX using independent two-tailed t-tests. The alpha level
for all analyses was set at 0.01.

Histology
At the end of each experiment, an iron deposit was made by passing direct anodic current
(100 μA for 10 sec) through the stimulating and recording electrodes, and 1.0 µl cresyl
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violet stain was infused through the cannula. Mice were then euthanized with a 0.25 ml
intracardial injection of urethane (0.345 g/ml). Brains were removed, immersed
overnight in 30%/10% sucrose/formalin plus 0.1% potassium ferricyanide until
sectioning. After fixation, 30 µm coronal sections were sliced in a cryostat at -30°C, and
placements of stimulating electrodes, recording electrodes, and drug infusion cannulae
were determined under a light microscope and recorded on representative coronal
diagrams (Paxinos and Franklin, 2001).

Chemicals
Urethane, CPP, CNQX, and MCPG were obtained from Sigma-Aldrich Chemical Co. (St
Louis, MO, USA). All chemicals, with the exception of urethane (distilled water), were
dissolved in sterile PBS (pH~7.4).

Results
Stereotaxic placements of infusion cannulae, recording and stimulating electrodes
Recording electrode placements (n = 16) were confined to the dorsal striatum (range in
mm: 1.34-1.54 anterior to bregma; 1.30-1.60 lateral to midline; 2.40-2.70 ventral to dura)
(Fig. 1A). Stimulating electrode tips (n = 16) were positioned within the STN (range in
mm: 1.94-2.18 posterior to bregma; 1.50-1.70 lateral to midline; 3.90-4.20 ventral to
dura) (Fig. 1B). Cannula tip placements (n = 16) were localized within the SNc (range in
mm: 2.92-3.16 posterior to bregma; 1.40-1.60 lateral to midline; 3.60-3.90 ventral to
dura) (Fig. 1C).
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Fig. 1. Representative coronal sections of the mouse brain (adapted from the atlas of
Paxinos and Franklin, 2001), with shaded areas indicating the placements of (A)
amperometric recording electrodes in the striatum, (B) stimulating electrodes in the
subthalamic nucleus (STN), (C) drug infusion cannulae in the substantia nigra compacta
(SNc). Numbers correspond to mm from bregma.

Effects of GluR blockade on STN stimulation-evoked dopamine efflux
Intra-SNc infusion of PBS (n = 4) did not significantly alter STN stimulation-evoked
striatal dopamine efflux from pre-infusion baseline levels (96.2% ± 1.7 at 5 min postinfusion, p = 0.110) (Fig. 2A and B). Infusion of the mGluR antagonist MCPG (2.0 µg; n
= 4) also had no significant effect on STN-evoked striatal dopamine efflux (97.1% ± 1.1
at 5 min post-infusion, p = 0.084) (Fig. 2A and B). However, intra-SNc infusion of the
NMDA receptor antagonist CPP (1.0 µg; n = 4) or the AMPA/kainate receptor antagonist
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CNQX (0.2 µg; n = 4) significantly decreased evoked dopamine efflux, reaching a
maximum of 60.1% ± 5.2 and 67.6% ± 2.3 respectively (p < 0.01) at 5 min post-infusion
(Fig. 2A and B). The peak percent change of STN stimulation-evoked dopamine striatal
release following intra-SNc CPP were not significantly different compared to the percent
change following CNQX infusion into the SNc (p = 0.23).

Fig. 2. Mean amperometric recordings of dopamine release in the striatum evoked by
electrical stimulation of the subthalamic nucleus (A) and corresponding mean peak
percentages (B) following substantia nigra compacta (SNc) microinfusions of phosphate-
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buffered saline (PBS, pH~7.4), the metabotropic glutamate receptor antagonist (+)methyl-4-carboxyphenylglycine (MCPG), the NMDA receptor antagonist (±)-3-(2carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), the AMPA/kainate receptor
antagonist 6-cyano-7-1fitroquinoxaline-2,3-dione (CNQX). Time zero indicates the start
of the stimulation (20 pulses at 50 Hz). * Significant change in striatal dopamine
concentration after infusion compared to pre-infusion baseline responses (100%).

Discussion
STN stimulation-evoked dopamine release in the striatum as measured using in vivo fixed
potential amperometry was significantly attenuated following infusion of an NMDA or
AMPA/kainate antagonist into the SNc. In contrast, intra-SNc infusion of an mGluR
antagonist, including drug vehicle (PBS), had no effect on STN stimulation-evoked
dopamine release in the striatum. The present results suggest that iGluRs in the SNc,
compared to mGluRs, play a more critical role in mediating relatively brief excitatory
glutamatergic activation of SNc dopamine neurons.

The role of SNc mGluRs in mediating nigrostriatal dopamine activity
The present finding that intra-SNc MCPG had no effect on STN stimulation-evoked
dopamine release in the striatum warrants consideration. The mGluRI subtype,
belonging to the Group I mGluRs, is the predominant mGluR subtype localized to SNc
dopamine cells (Kosinski et al., 1998; Testa et al., 1994), justifying the use of the Group I
and II antagonist MCPG (Pin and Duvoisin, 1995; Riedel, 1996). Furthermore, we
utilized a dose of MCPG that has been effective in abolishing accumbal basal dopamine
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efflux as evoked by electrical stimulation of the ventral subiculum of the hippocampus
(Blaha et al., 1997). Consequently, the results of the present study imply that mGluRs in
the SNc are not employed by STN glutamatergic afferents to mediate striatal dopamine
efflux. Previous studies on the role of SNc mGluR receptors in nigrostriatal dopamine
activity are somewhat conflicting. The activation of mGluR1 subtype in the SNc has
been shown to both excite and inhibit dopamine neurons (Fiorillo and Williams, 1998;
Guatteo et al, 1999; Meltzer et al., 1997), while the activation of Group II mGluRs at
STN-SNc synapses, most likely located presynaptically on glutamatergic terminals,
inhibits glutamatergic transmission in SNc dopamine neurons (Bonci et al, 1997; Wang et
al., 2005). Our utilization of fixed potential amperometry allows for the measurement of
phasic dopamine release, rather than basal extracellular levels of dopamine. Thus, the
rapid responses seen with STN-stimulation, generating burst firing of SNc dopamine
neurons, are most likely not affected by the complex, relatively slower, actions of
mGluRs. While the findings of the present study are strengthened by similar previous
findings that intra-SNc MCPG had no effect on brief PPT stimulation-evoked striatal
dopamine release (Forster and Blaha, 2003), further studies involving various doses of
MCPG and other mGluR antagonists are needed before the use of mGluRs by STN
projections to the SNc can be excluded. In this regard, it is significant to note that
prolonged stimulation of the STN has been shown to result in an initial short duration
increase in phasic striatal dopamine release (~1 sec) that is followed by a lower but still
elevated level of dopamine release (Lee et al., 2006). This later inhibition of stimulationevoked phasic dopamine release was thought to reflect compensatory effects at the level
of the SNc glutamate-containing terminal. Theoretically, activation of group II and III
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mGluRs on glutamate-containing terminals may attenuate dopamine cell activity by
reducing excessive glutamate release onto dopamine cells in the SNc, despite a
continuous level of firing activity (Grillner and Mercuri, 2002; Mercuri et al., 1993).

The role of SNc iGluRs in mediating nigrostriatal dopamine activity
Both NMDA and non-NMDA receptors were shown to be involved in STN stimulationevoked dopamine in the striatum, as evidenced by significantly attenuated responses
following intra-SNc NMDA or AMPA/kainate receptor antagonists. The present results
also indicate that NMDA and AMPA/kainate receptor subtypes have an equal role in
modulating excitatory glutamatergic inputs arising from the STN, as the maximum
percent decreases in STN-evoked striatal dopamine release post-infusion did not differ
between the NMDA and AMPA/kainate receptor antagonists. Activation of AMPA and
kainate receptors opens membrane ion-channels to allow the rapid influx of positively
charged sodium resulting in the generation of fast moment-to-moment excitatory postsynaptic potentials (Borges and Dingledine, 1998). NMDA receptors are highly
conductive to the positive ion calcium, although the entry of calcium in the resting state is
blocked by magnesium (Chapman, 2009). Usually, activation of NMDA receptors
requires colocalised AMPA/kainate receptors to depolarise first so that the entry of
positive sodium displaces magnesium ions from the NMDA ion pore thus permitting
calcium influx into the cell, consequently depolarizing it (Michaelis, 1998). Thus, a
similar degree of attenuation in STN-evoked striatal dopamine following blockade of
SNc NMDA or AMPA/kainate receptors in the present study is not surprising. Previous
research has shown that synaptic potentials in dopamine neurons evoked by single
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stimulating pulses are mediated predominantly by activation of AMPA/kainate receptors
and to a smaller extent through NMDA receptor activation (Johnson and North, 1992;
Mereu et al, 1991). Whereas, a preferential role for NMDA receptors, compared to nonNMDA receptors, in producing burst activity in SNc dopamine neurons has been
described (Chergui et al., 1994; Overton and Clark, 1997). It is possible that activation of
NMDA receptors requires a larger amount of glutamate release than non-NMDA
receptors, as high frequency stimulation, perhaps corresponding with burst firing, is
required to evoke synaptic potentials with a large contribution of NMDA receptors
(Grillner and Mercuri, 2002). Nonetheless, it seems that glutamatergic excitation of
dopamine neurons in the SNc, and subsequent striatal dopamine release, is mediated to
some degree by both NMDA and AMPA/kainate receptors, as widespread distribution of
both types of these subtype receptors on dopaminergic neurons in the SNc has been well
established (Chatha et al., 2000).

Conclusions
The present results suggest that NMDA and AMPA/kainate receptors both play a
significant role in modulating striatal dopamine release evoked by electrical stimulation
of the STN. Because glutamate receptors mediate synaptic transmission in the SNc, a
vital site in the extrapyramidal motor circuit, pharmacological manipulation of these
receptors may be able to alter dysfunctional neurotransmission and thus provide a
promising therapeutic target for treating Parkinson’s disease. Animal model studies
suggest that altering the activity of these receptors pharmaceutically may serve to
alleviate parkinsonian motor symptoms or perhaps even slow disease progression by
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delaying dopamine neuron degeneration, thought to be associated with excitotoxicity
caused by relatively high extracellular levels of glutamate. For example, antagonists of
NMDA and AMPA receptors have been shown to reverse motor symptoms and
levodopa-induced dyskinesias in animal models (Gossel et al., 1995; Klockgether and
Turski, 1990; Schwarz et al., 1996), as would be expected given the findings of the
present study. Although blocking SNc mGluRs had no effect on STN stimulation-evoked
striatal dopamine release in the present study, pharmaceutical modulation of mGluRs
have shown promise in providing neuroprotection of SNc dopamine neurons in animal
models of Parkinson’s disease (Johnson et al., 2009), further suggesting a role for
mGluRs, located presynaptically, in maintaining functional basal glutamate levels in the
SNc (Grillner and Mercuri, 2002; Mercuri et al., 1993). Therefore, GluRs represent
promising targets for the development of nondopaminergic pharmaceutical therapies for
the treatment of Parkinson’s disease, and more studies are necessary to determine the
relative contributions of each receptor subtype in mediating afferent activation of the
nigrostriatal dopamine system.
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Chapter 7. Summary, Conclusions, and Implications for Future Research

The experimental studies of Chapters 5 and 6 were undertaken to investigate important
neural circuits that functionally contribute to phasic dopamine neurotransmission within
the nigrostriatal dopaminergic system. These investigations were conducted with the
purpose of extending current knowledge of the neural connectivity of nuclei, specifically
the substantia nigra compacta (SNc), subthalamic nucleus (STN), and pedunculopontine
tegmental nucleus (PPT), with projections that mediate striatal dopamine release and
subsequently influence activity of the basal ganglia-thalamocortical motor circuit. This
chapter presents an overview of the present findings and their functional implications to
pharmaceutical and surgical treatments for the motor symptoms of Parkinson’s disease.
Overall, using in vivo fixed potential amperometry the present studies show that
electrical stimulation of the dorsal portion of the medial forebrain bundle (MFB), STN, or
PPT, all of which are targets for clinical deep brain stimulation (DBS) procedures as a
treatment for the motor symptoms of Parkinson’s disease, elicits dopamine release in the
dorsal striatum. Stimulation of the MFB, which consists of axons of ascending SNc
dopamine neurons that project closely along the dorsal surface of the STN to the striatum,
was investigated as a control for STN stimulation, as it has been suggested that DBS of
the MFB may optimally enhance dopamine transmission in the basal ganglia, thus
providing better therapeutic results compared to DBS of the STN (Lee et al., 2006). The
present findings confirm that MFB high frequency stimulation (HFS)-evoked striatal
dopamine release is mediated predominately by activation of ascending SNc dopamine
neurons, independent of activity within the SNc and PPT. Striatal dopamine release
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elicited by STN or PPT stimulation, however, occurs via more complicated neural
interactions, which are likely involved in the underlying mechanisms of STN or PPT
DBS as a treatment for the tremor, gait and postural symptoms of Parkinson’s disease.
Reductions in striatal dopamine release following pharmacological blockade of axonal
transmission or cholinergic/glutamatergic receptor populations was used to determine the
specific involvement of the SNc, STN, and PPT in mediating HFS-evoked striatal
dopamine release. The influence of these subcortical nuclei and their intrinsic receptor
mechanisms on STN or PPT-driven nigrostriatal dopamine transmission is presented
below.

Subcortical Involvement in STN HFS-Evoked Nigrostriatal Dopamine Transmission
The present studies examined several neuronal circuits in the mid- and hindbrain that
could be involved in STN HFS-evoked dopamine release in the striatum. Results
confirmed that STN stimulation is dependent on activities of both the SNc and PPT, as
pharmacological blockade of axonal transmission within either of these nuclei
significantly decreased STN-evoked striatal dopamine efflux compared to pre-infusion
baseline responses. Thus, these findings suggest that stimulation of the STN works by
activating the SNc directly via excitatory STN-SNc projections and indirectly via
excitatory STN-PPT projections that, in turn, provide excitatory PPT inputs to SNc
dopamine cells. The relative contributions of the direct and indirect projections to the
SNc that are involved in mediating STN HFS-evoked dopamine release are summarized
in Fig. 1A. The present data highlight the significance of the PPT in STN HFS-evoked
striatal dopamine release as neuronal projections through the PPT mediate roughly half
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(45.9%) of STN HFS-evoked dopamine release in the striatum. As expected STNevoked striatal dopamine release is almost fully dependent upon activation of dopamine
cells in the SNc; however, blockade of axonal transmission within the SNc did not
completely abolish STN HFS-evoked striatal dopamine release. Under the present
experimental conditions, it is likely that a single infusion of lidocaine or receptor
blocking drug failed to inactivate the entire SNc, as well as unavoidable stimulation of
some of the dopamine axons within the MFB that may also have contributed to the
response elicited by STN stimulation. It is important to note that in previous
amperometric recording of STN stimulation-evoked dopamine release in rats (Lee at al.,
2006), this was avoidable given the relatively larger size of the STN in rats, compared to
mice.

Fig. 1. Summary of relative contributions of neuronal projections mediating subthalamic
nucleus (STN) (A) and pedunculopontine tegmental nucleus (PPT) (B) HFS-evoked
dopamine release in the striatum (stri). ACh: acetylcholine; Glu: glutamate; m/nAchR:
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muscarinic or nicotinic acetylcholine receptor; iGluR: ionotropic glutamate receptor;
SNc: substantia nigra compacta.

PPT receptor mechanisms mediating STN HFS-evoked nigrostriatal dopamine
transmission
Although the present studies only included intra-PPT infusions of lidocaine, rather than
receptor antagonists, previous studies have shown that the PPT receives glutamatergic
projections from the STN and prefrontal cortex (Kita and Kitai, 1987; Sesack et al.,
1989), as well as GABAergic projections from the substantia nigra reticulata (SNr) and
globus pallidus (Kang and Kitai, 1990; Moriizumi and Hattori, 1992). Both NMDA and
AMPA receptors have been shown to be located on cholinergic and glutamatergic cells
within the PPT, and activation of both types of iGluRs increase PPT activation (Steiniger
and Kretschmer, 2003) (see Fig. 2); however, activation of both A and B GABA receptor
subtypes has been shown to inhibit activity of PPT neurons, although the precise location
of these GABA receptors in the PPT remain unclear (Saitoh et al., 2003). Furthermore,
mAchRs (specifically of the M2 family) have been localized presynaptically on PPT
cholinergic neurons (Vilaro et al., 1992). Intra-PPT infusions of the non-selective
mAChR antagonist scopolamine enhances striatal dopamine release and dopaminedependent behaviors such as locomotion and stereotypy; both of which can be blocked by
the cholinergic agonist carbachol infused into the PPT (Chapman et al., 1997; Mathur et
al., 1997). These mAChRs are most likely autoreceptors of the M2 family as intra-PPT
infusion of the M2/4 selective mAChR antagonist methoctramine has been shown to
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enhance striatal dopamine release (Miller and Blaha, 2004). Activation of M2-like
mAChRs in the PPT results in hyperpolarization of mesopontine cholinergic cells
(Luebke et al., 1993; Leonard and Llinas, 1994) and a net decrease in excitation to SNc
dopaminergic cells resulting in lowered extracellular levels of striatal dopamine (Forster
and Blaha, 2003). Therefore, M2-like mAChRs are thought to function as cholinergic
autoreceptors involved in feedback inhibition at the level of PPT cholinergic cells,
serving as regulators of information received by the PPT.
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Fig. 2. Simplified basal ganglia circuitry depicting the muscarinic/nicotinic acetylcholine
receptors (m/nAchRs), ionotropic/metabotropic glutamate receptors (i/mGluRs), and
GABA-A/B receptors within the substantia nigra (SN), subthalamic nucleus (STN), and
pedunculopontine tegmental nucleus (PPT) responsible for mediating nigrostriatal
dopamine activity. + indicates excitatory effects upon receptor activation, and – indicates
inhibitory effects upon receptor activation. Note that the GABAergic projection from the
globus pallidus externus to the STN has been omitted for clarity; however, activation of
mAchRs on these incoming terminals has been shown to excite STN neurons by
inhibiting GABA release in the STN (Shen and Johnson, 2000). Thus, mAchRs located
presynaptically on GABA terminals in the STN are receptors that mediate increases in
dopamine activity not listed in this figure. References corresponding to citation numbers:
1: Picciotto et al., 1999; 2: Meltzer et al., 1997; 3: Schilstrom et al., 2003; 4: Paladini et
al., 1999; 5: Forster et al., 2001; 6: Grillner and Mercuri, 2002; 7: Chergui et al., 1994; 8:
Kearney and Albin, 2000; 9: Steiniger and Kretschmer, 2003; 10: Yin and French, 2000;
11: Bonci and Malenka, 1999; 12: Manzoni and Williams, 1999; 13: Prior and Singh,
2000; 14: Charara et al., 2000; 15: Miller and Blaha, 2004.

Subcortical Involvement in PPT HFS-Evoked Nigrostriatal Dopamine Transmission
The present results show that PPT HFS-evoked striatal dopamine release is significantly
dependent on activities of the SNc and STN, as inactivation of the SNc or the STN both
led to significant decreases in PPT-evoked striatal dopamine efflux compared to pre-drug
infusion baseline responses. Thus, these findings suggest that clinical DBS of the PPT
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may involve activation of the SNc directly via excitatory PPT-SNc projections and
indirectly via excitatory PPT-STN projections that, in turn, provide excitatory inputs to
SNc dopamine cells. The relative contributions of the direct and indirect projections to
the SNc that are involved in mediating STN HFS-evoked dopamine release are
summarized in Fig. 1B. As expected PPT HFS-evoked dopamine release in the striatum
is almost fully dependent upon activation of dopamine cells in the SNc, either directly or
indirectly. The present data again highlight the significance of the PPT-STN reciprocal
connectivity, as neuronal projections through the STN mediate 50.0% of the PPT HFSevoked dopamine release in the striatum. Thus, the present results suggest that the
connectivity of the PPT and STN may be equally as important as the connectivity
between the PPT and SNc; however, the neurochemical nature of this pathway has
received historically less attention compared to the PPT-SNc projections. For this reason,
the present studies included experiments designed to distinguish the neurotransmitters
involved in activating the STN following PPT HFS.

STN receptor mechanisms mediating PPT HFS-evoked nigrostriatal dopamine
transmission
In further examining the excitatory glutamatergic and cholinergic pathway from the PPT
to the STN, the present findings suggest that PPT HFS-evoked striatal dopamine release
is dependent upon both glutamate receptors (GluRs) and acetylcholine receptors (AchRs)
in the STN, as intra-STN GluR antagonists or AchR antagonists both significantly
decreased PPT-evoked striatal dopamine release by 22.5% or 25.8%, respectively. Thus,
it seems that combined glutamatergic and cholinergic projections from the PPT to the
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STN mediate approximately half of PPT-evoked dopamine release in the striatum.
Although the use of broad-spectrum receptor antagonists in these studies precludes
identification of specific receptor subtypes, both ionotropic and metabotropic GluRs
(i/mGluRs) have been found in the STN (Gotz et al., 1997; Testa et al., 1994). All iGluR
subtypes, which are N-methyl-D-aspartic acid (NMDA), -amino-3-hydroxyl-5-methyl4-isoxazole-propionate (AMPA), and kainate (with the latter 2 sometimes collectively
referred to as non-NMDA receptors), have been localized postsynaptically within the
STN (Albin et al., 1989; Clarke and Bolam, 1998). Activation of either NMDA and nonNMDA receptors is thought to excite STN neurons, as studies utilizing in vitro slice
preparations show that the application of both NMDA and non-NMDA glutamatergic
antagonists reduce excitatory firing of STN neurons (Chergui et al., 1994; Shen and
Johnson, 2000). Future studies recording PPT HFS-evoked striatal dopamine release
before and after intra-STN infusion of specific NMDA or AMPA/kainate receptor
antagonists would help to determine the relative extent to which these iGluRs within the
STN mediate pathways important to modulating striatal dopamine activity from PPT
glutamatergic afferents.
The mGluRs are subdivided into 3 groups, I, II, and III, all of which are expressed
to some degree in the STN (Testa et al., 1994). The mGluRI and mGluRIII receptors are
thought to be located postsynaptically and presynpatically, respectively, while the
mGluRII are thought to be located both presynaptically and postsynaptically (Cartmell
and Schoepp, 2000; Wang et al., 2000). Activation of mGluRs in the STN has been
shown to both increase and inhibit excitation of STN glutamate neurons (Abbott et al.,
1997; Awad et al., 2000; Awad-Granko and Conn, 2001). Although the localization of

81

STN mGluRs and their role in mediating nigrostriatal dopamine release is unclear, it has
been suggested that activation of presynaptic mGluRIII subtypes on glutamate terminals
reduces STN activity while activation of postsynaptic mGluRII subtypes increases STN
activity (Kearney and Albin, 2000). The effects of STN mGluR activation on STN
activity and dopamine-related behaviors appears to be occurring through several
mechanisms that are still unclear (Kearney and Albin, 2000); therefore, future studies
recording PPT HFS-evoked striatal dopamine release before and after infusion of
selective mGluR antagonists would be useful in elucidating their role in mediating
nigrostriatal dopamine transmission.
The use of a combination of broad-spectrum AchR antagonists in the present
studies also prevented identification of the specific STN muscarinic and nicotinic AchRs
(m/nAchRs) utilized by PPT afferents to the STN. Cholinergic agonists such as
carbachol have been shown to excite STN neurons (Flores et al., 1996); however, nAchR
agonists alone had no apparent effect on neuronal cell activity in the STN (Feger et al.,
1979). Furthermore, the mAchR antagonist scopolamine, but not the nAchR antagonist
mecamylamine, have been shown to block acetylcholine-evoked STN cell excitations
(Feger et al., 1979); thus, it may be postulated that STN AchRs are primarily muscarinic
(see Fig. 2). The M3 mAchR subtype, in particular, is prominently expressed in the STN
(Levey et al., 1994), and Shen and Johnson (2000) found that the mAchR agonist
muscarine reduced the amplitude of GABA inhibitory postsynaptic currents, while the
effect was blocked by the non-subtype specific mAchR antagonist scopolamine as well as
an M3 specific mAchR antagonist. These investigators concluded that muscarinic
agonists in the STN act at presynaptic M3 mAchRs on GABA afferents, causing
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disinhibition (excitation) of STN neurons, thereby permitting afferents from the PPT to
have a greater excitatory influence on STN output. Thus, STN mAchRs, particularly of
the M3 subtype, may be involved in the indirect activation of SNc dopaminergic cells via
PPT-STN-SNc pathways (Shen and Johnson, 2000).

SNc Receptor Mechanisms Mediating STN and PPT HFS-Evoked Nigrostriatal
Dopamine Transmission
Intra-SNc infusions of specific GluR and AchR antagonists helped to uncover the SNc
receptor mechanisms that mediate STN and PPT HFS-evoked striatal dopamine release.
The present findings suggest that activation of both GluRs and AchRs in the SNc is
involved nigrostriatal dopamine transmission elicited by STN or PPT stimulation. In
regards to GluRs, the present results suggest that iGluRs in the SNc, compared to
mGluRs, play a more critical role in mediating relatively brief excitatory glutamatergic
activation of SNc dopamine neurons. Fig. 2 illustrates i/mGluRs, m/nAchRs, and GABA
receptors within the SNc and SNr responsible for mediating nigrostriatal dopamine
activity. Both NMDA and non-NMDA receptors were shown to be involved in STN
HFS-evoked dopamine in the striatum, as evidenced by significantly attenuated responses
following intra-SNc NMDA or AMPA/kainate receptor antagonists. These findings were
not surprising given that widespread distribution of both types of these subtype iGluRs on
dopaminergic neurons in the SNc has been well established (Chatha et al., 2000).
However, the present finding that infusion of an mGluR antagonist into the SNc
had no effect on STN HFS-evoked dopamine release in the striatum warrants
consideration. Previous studies on the role of SNc mGluR receptors in nigrostriatal
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dopamine activity are somewhat conflicting, as activation of mGluRs in the SNc has
elicited both excitation and inhibition of nigrostriatal dopamine activity (Bonci et al,
1997; Fiorillo and Williams, 1998; Guatteo et al, 1999; Meltzer et al., 1997; Wang et al.,
2005). The mGluRI subtype is the predominant mGluR subtype localized to SNc
dopamine cells (Kosinski et al., 1998; Testa et al., 1994); however, group II and III
mGluRs are thought to be located presynaptically within the SNc (Mercuri et al., 1993).
Activation of group II and III mGluRs on glutamate-containing terminals may attenuate
dopamine cell activity by reducing excessive glutamate release onto dopamine cells in the
SNc, despite a continuous level of firing activity (Grillner and Mercuri, 2002; Mercuri et
al., 1993). Indeed, continuous HFS of the STN has been shown to elicit a rapid increase
in striatal dopamine release that quickly abates within two seconds of stimulation to
approximately one-third the peak height of the initial increase (Lee et al., 2006), possibly
reflecting a delayed inhibitory presynaptic regulation of glutamate release. Thus, it is
possible that the the relatively rapid (~1 sec duration) responses seen in the present
studies utilizing in vivo fixed potential amperometry with STN-stimulation are not
affected by the complex, relatively slower, actions of mGluRs. Further studies utilizing
longer term stimulation and selective mGluR antagonist infusions into the SNc are
needed to clarify the role of these receptors mediating STN and/or PPT activation of SNc
dopamine neurons, particularly in consideration that conventional DBS involves
continuous stimulation of target structures.
The use of broad-spectrum mAchR and nAchR antagonists in the present studies
also did not permit identification of the specific receptor subtypes utilized by PPT
afferents to the SNc. However, excitation of midbrain dopaminergic neurons by
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muscarine has been shown to be mediated by M1-like receptors (Lacey et al., 1990), and
given that relatively high expression levels of mRNA for the M5 mAchR subtype in the
SNc and the finding that the M5 subtype is the only mAchR to be definitively localized
on SNc dopaminergic cells (Reever et al., 1997; Vilaro et al., 1990), SNc mAchRs of the
M5 subtype are thought to be involved in the release of striatal dopamine following PPT
stimulation (Forster et al., 2001; Forster and Blaha, 2003). Nicotine administered locally
into the SNc increases the firing of SNc dopaminergic neurons and enhances
concentrations of dopamine metabolites in the striatum (Lichtensteiger et al., 1976,
1982). Several nAchR subunits, such as α3 to α7 and β2 to β3, have been shown to be
present in the SNc (Champtiaux et al., 2002; Charpantier et al., 1998; Goldner et al.,
1997; Klink et al., 2001; Wonnacott et al., 2006). In particular, cholinergic inputs from
the PPT may enhance nigrostriatal dopaminergic transmission via activation of α4β2 and
α7 nAchRs localized on dopaminergic cells in the SNc (Livingstone and Wonnacott,
2009).

Implications of the Current Findings to Parkinson’s Disease and DBS
Furthering the current state of knowledge on the interconnectivity between important
neural structures which can functionally influence nigrostriatal dopamine transmission
allows for insight into potential pharmacological and surgical treatment of basal gangliarelated disorders, such as Parkinson’s disease. Results from the series of experiments in
Chapters 5 and 6 add to the growing body of evidence supporting an important role of the
STN and PPT in modulating striatal dopamine release and subsequent output from the
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basal ganglia to the thalamus and motor areas of the cortex, thus influencing motor
functioning.

Glutamatergic and cholinergic receptor subtypes as targets for the treatment of
Parkinson’s disease
As the present results suggest that NMDA and AMPA/kainate receptors both play a
significant role in modulating striatal dopamine release evoked by HFS of the STN,
pharmacological manipulation of these receptors may be able to alter dysfunctional
neurotransmission and thus provide a promising therapeutic target for treating
Parkinson’s disease. For example, antagonists of NMDA and AMPA receptors have
been shown to reverse motor symptoms and levodopa-induced dyskinesias in
parkinsonian animal models (Gossel et al., 1995; Klockgether and Turski, 1990; Schwarz
et al., 1996). Animal model studies also suggest that altering the activity of these
receptors pharmaceutically may even serve to slow disease progression by delaying
dopamine neuron degeneration, thought to be associated with excitotoxicity caused by
relatively high extracellular levels of glutamate. Specifically, NMDA receptors are
known to mediate excitotoxicity caused by high levels of glutamate. Therefore,
activation of these receptors in the SNc may contribute to the degeneration of dopamine
neurons in this region (Waxman and Lynch, 2005). In support of this argument, NMDA
antagonists have been noted to reduce or delay SNc degeneration and motor deficits
caused by MPTP administration or 6-OHDA lesioning (Johnson et al., 2009). Thus,
blockade of NMDA receptors have been suggested to be a potentially useful strategy for
slowing disease progression. However, the widespread expression and diverse functional
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roles of NMDA receptors raise concern that targeting these receptors would lead to
serious unwanted side effects. Clinical studies have therefore used weak NMDA receptor
antagonists and have generally failed to find any therapeutic benefit when administered
alone (without levodopa) (Johnson et al., 2009). More promising studies suggest that
selectively targeting NMDA receptor subtypes specific to regions relevant to Parkinson’s
disease pathophysiology may represent safer neuroprotective options (Jin et al., 1997).
As such, further clinical studies using more selective drugs targeting NMDA receptors
are warranted. Although blocking SNc mGluRs had no effect on relatively brief STN
HFS-evoked striatal dopamine release in the present study, pharmaceutical modulation of
mGluRs have shown promise in providing neuroprotection of SNc dopamine neurons in
animal models of Parkinson’s disease (Johnson et al., 2009), further suggesting a role for
mGluRs, located presynaptically on glutamate terminals in the STN, in maintaining
functional non-toxic basal glutamate levels in the SNc (Grillner and Mercuri, 2002;
Mercuri et al., 1993). Therefore, GluRs represent promising targets for the development
of nondopaminergic pharmaceutical therapies for the treatment of Parkinson’s disease,
and more studies are necessary to determine the relative contributions of each receptor
subtype in mediating afferent activation of the nigrostriatal dopamine system.
Given the well known functional interactions of the cholinergic systems with the
nigrostriatal dopaminergic system (for review see Lester et al., 2010), selective
pharmaceutical agents acting on the various AchR subtypes existing heterogeneously at
key anatomical sites in the brain also represent promising pharmaceutical targets in the
treatment of Parkinson’s disease. Historically, anticholinergics were the first available
drugs for the alleviation of Parkinson’s symptoms, and are still used as secondary
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treatments for Parkinson’s disease in conjunction with other antiparkinsonian drugs
(Katzenschlager et al., 2003). Centrally-acting anticholinergics, all specific for mAchRs,
include benztropine (Cogentin), which is widely prescribed, and biperiden (Akineton),
orphenadrine (Norflex), and procyclidine (no longer prescribed in the U.S.) (Deleu et al.,
2002). Anticholinergic drugs have been used mainly in tremor-predominant cases of
Parkinson’s disease and are thought to act by counterbalancing the reduced dopaminergic
influence on the medium spiny GABAergic output neurons to the globus pallidus
(Clarke, 2002; Lees, 2005). Parkinsonian symptoms in mice induced by mAchR agonists
can be reduced by systemic administration of a broad-spectrum mAchR antagonist, as
well as a mAchR antagonist with moderate selectivity for the M4 mAchR (Betz et al.,
2007).
Furthermore, findings that parkinsonian-like symptoms in mice can be reduced by
systemic administration a broad-spectrum mAchR antagonist, as well as a mAchR
antagonist with moderate selectivity for the M4 mAchR suggests that blockade of M4
mAchR may be beneficial in reducing parkinsonian symptoms (Betz et al., 2007).
However, systemic administration prevents the identification of the neural location at
which the receptors are being blocked. Intra-PPT infusions of the non-selective mAchR
antagonist scopolamine enhances striatal dopamine release and dopamine-dependent
behaviors such as locomotion and stereotypy; both of which can be blocked by the
cholinergic agonist carbachol infused into the PPT (Chapman et al., 1997; Mathur et al.,
1997). These mAchRs are most likely autoreceptors of the M2 family (M2 and M4) as
M2 receptors have been localized presynaptically on PPT cholinergic neurons (Vilaro et
al., 1992, 1994), and intra-PPT infusion of the M2/4 selective mAchR antagonist

88

methoctramine has been shown to enhance striatal dopamine release (Miller and Blaha,
2004). Therefore, M2/4 mAchRs are thought to function as cholinergic autoreceptors
involved in feedback inhibition at the level of PPT cholinergic cells, regulating
information received by the PPT. Blocking these mAchR within the PPT and
subsequently increasing PPT activation of SNc dopamine neurons may be therapeutically
beneficial for treating the motor symptoms of Parkinson’s disease as reduced excitatory
cholinergic output from the PPT has been found to result in parkinsonian-like postural
deficits, hypokinesia, and locomotor deficits in primates (see Pahapill and Lozano, 2000).
Furthermore, cholinergic neurons in the PPT are reduced by nearly 40% in Parkinson’s
patients, and a significant loss of PPT neurons has been found to correlate with the extent
of neuronal loss of dopaminergic cells in the SNc and the severity of Parkinson’s disease
symptoms (Rinne et al., 2008; Zweig et al., 1989). In sum, increasing activation of PPT
neurons via blockade of mAchRs may relieve the motor symptoms of Parkinson’s disease
by increasing activity of the remaining PPT projection neurons to SNc dopamine
neurons.
Findings from animal studies also suggest that nicotine or nAchR agonists may be
an effective treatment for the motor symptoms of Parkinson’s disease. Stimulation of
nAchRs has been shown to modulate locomotor activity in intact nonlesioned animals as
well as ameliorate motor dysfunctions in animals with nigrostriatal damage (Meshul et
al., 2002; Schneider et al., 1998). Additionally, studies have shown that people who
smoke, or have smoked regularly, are 50% less likely to develop Parkinson’s disease than
those who have never smoked, and nicotine has been found to alleviate parkinsonian
cognitive and motor symptoms once Parkinson’s disease has developed (see Janhunen
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and Ahtee, 2007). The mechanisms underlying these therapeutically beneficial qualities
of nicotine are not known. Smoking and nicotine treatment have been shown to protect
the nigrostriatal dopaminergic neurons from degeneration following MPTP or 6-OHDA
treatment (Costa et al., 2001; Parain et al., 2003). However, acute or short-term treatment
with nicotine has shown little to no effects on motor activity in Parkinson’s patients or
parkinsonian animal models, suggesting that nicotine treatment may only provide a
neuroprotective and/or restorative effect with chronic use (see Quik et al., 2007).

Mechanism of action of deep brain stimulation as a treatment for Parkinson’s disease
The present studies show that HFS of the MFB, STN, or PPT elicits dopamine release in
the dorsal striatum. In relation to DBS as a treatment for Parkinson’s disease, the present
findings add support for the “dopamine release” hypothesis which proposes that DBS
improves motor symptoms related to Parkinson’s disease, in part, by activating surviving
nigrostriatal dopamine neurons and subsequently increasing striatal dopamine release
(Lee et al., 2009; Shah et al., 2010). The present results indicate that MFB stimulation is
mediated predominantly by activating ascending SNc dopamine axons, while STN
stimulation evokes striatal dopamine release directly via excitatory glutamatergic inputs
to SNc dopamine cells as well as, to a lesser degree, indirectly by activating excitatory
glutamatergic and cholinergic STN-PPT-SNc pathways. PPT stimulation evokes striatal
dopamine release directly by activating glutamatergic and cholinergic pathways to SNc
dopamine cells as well as indirectly via activation of glutamatergic and cholinergic PPTSTN-SNc projections. These data may help to explain the clinical improvements in
motor symptoms of Parkinson’s patients following stimulation of the border and white
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matter dorsal to the STN (notably the zona incerta) (Herzog et al., 2004; Saint-Cyr et al.,
2002; Voges et al., 2002) and may further suggest that DBS dorsal to the STN (within the
MFB), rather than within the STN proper, may be optimal in increasing striatal dopamine
levels for therapeutic benefits of Parkinson’s disease (Lee et al., 2006).
The present findings also add further support for the PPT as a potential target for
DBS as a treatment for certain motor symptoms of Parkinson’s disease, as PPT
stimulation elicited dopamine release in the striatum similar in magnitude to that of STN
stimulation. The dual stimulation of the STN and PPT in clinical DBS procedures is an
interesting and promising approach given the connectivity between the two nuclei
highlighted in these studies (Stefani et al., 2007). A better understanding of the neural
connectivity and mechanisms involved in DBS could potentially revolutionize the
procedure and lead to much greater clinical efficacy. For example, expanding on the
implications of the dopamine release hypothesis could lead to the next generation of DBS
devices in which the system can monitor dopamine neurotransmission during stimulation,
thus providing a neurochemical sensing feedback mechanism to maintain dopamine
concentrations in the striatum at optimal levels for therapeutic efficacy (Lee et al., 2009).

Future Directions and General Conclusions
Integrity of the nigrostriatal dopamine pathway is critical for the normal
processing of sensory-motor information, with disruptions leading to neurological motor
disorders, such as Parkinson’s disease. The nigrostriatal dopamine pathway and other
nuclei within the basal ganglia have many functionally critical interconnections as well as
extensive connections with mesopontine glutamatergic and cholinergic pathways, to the
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extent that pathology of the PPT is correlated with the motor symptoms of Parkinson’s
disease (Rinne et al., 2008; Zweig et al., 1989). The electrochemical technique applied in
the experiments in Chapters 5 and 6 has provided a method with which to confirm and
extend research investigating the neuronal pathways and receptor mechanisms involved
in HFS-evoked nigrostriatal dopamine transmission. Findings have thus indicated a
complex role of glutamatergic and cholinergic afferents from the STN and PPT in
modulating dopamine release in the striatum via direct and indirect routes to the SNc.
Together with what is known of the physiological role of i/mGluRs and m/nAchRs in the
STN, PPT, and SNc, results highlight the need for further development and application of
selective ligands.
The purpose of these studies was to explore the functional interconnectivity
between nuclei involved in afferent regulation of nigrostriatal transmission. Therefore, it
was necessary to use an intact brain, rather than in vitro slice preparations, so that normal
neuronal influences on nigrostriatal dopamine release were maintained giving more
ecological validity to the measures (Beurrier et al., 2006). However, it has been noted
that a possible limitation of in vivo monitoring is that it requires deep anaesthesia of
animals which may increase the inhibitory responses of the central nervous system (West,
1998). However, this limitation has been minimized by the use of the anaesthetic
urethane which has been shown to not interfere with dopamine functioning (Sabeti et al.,
2003). Still, the evaluation of STN or PPT HFS-evoked striatal dopamine release,
perhaps coupled with behavioral studies, in freely-moving animals would completely
eliminate the issue of anaesthetic interference while further elucidating the behaviorally
functional roles of the GluRs and AchRs identified in the present studies. Furthermore,
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as the present studies were conducted in intact animals, the applicability of the
conclusions is limited. Importantly, we have shown that HFS of the STN can elicit
measurable dopamine release in the striatum of 6-OHDA lesioned animals, and the
amount of HFS-evoked dopamine release correlated with the extent of 6-OHDA-induced
denervation (Blaha et al., 2008). Therefore, future experiments using the present
neurochemical recording procedures in 6-OHDA lesioned mice are feasible and would
provide knowledge of the involvement of these pathways in an animal model of
Parkinson’s disease.
Nonetheless, the findings of the present studies shed considerable light on the
neural connectivity as well the receptor mechanisms involved in mediating HFS-evoked
nigrostriatal dopamine transmission. Understanding the influence of the STN and PPT
on SNc dopamine cell activity and output of the basal ganglia-thalamocortical motor
circuit may lead to novel pharmaceutical therapies as well as a better understanding of the
underlying mechanisms of clinical DBS of the MFB, STN, and the interconnected PPT;
both of which could lead to improvements the therapeutic efficacy of neuroprotective and
symptomatic treatments for Parkinson’s disease.
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